

Complementary Medicines References

- Therapeutic Goods Administration. Complementary medicines. At: www.tga.gov.au/topics/complementary-medicines
- NPS MedicineWise. Complimentary medicines explained. 2022. At: www.nps.org.au/consumers/complementary-medicines-explained
- National Health and Medical Research Council. Talking with your patients about complementary medicine - a resource for clinicians. Canberra: NHMRC; 2014. At: www.nhmrc.gov.au/about-us/publications/talking-your-patients-about-complementary-medicine-resource-clinicians
- Cancer Council Australia. Position statement: complementary and alternative therapies. 2013. At: http://wiki.cancer.org.au/policy/Position_statement_-_Complementary_and_alternative_therapies
- Therapeutic Goods Administration. Overview of the regulation of listed medicines and registered complementary medicines. Canberra: TGA; 2021. At: www.tga.gov.au/resources/resource/guidance/overview-regulation-listed-medicines-and-registered-complementary-medicines
- World Health Organization. WHO traditional medicine strategy 2014–2023. Geneva: WHO; 2013. At: www.who.int/publications/i/item/9789241506096
- Saper RB. Overview of herbal medicine and dietary supplements. UpToDate; [updated 23 Oct 2021]. At: www.uptodate.com/contents/overview-of-herbal-medicine-and-dietary-supplements?search=overview%20of%20herbal%20medicine%20and%20dietary%20supplements&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1#H14
- Therapeutic Goods Administration. Equivalence of herbal extracts in complementary medicines. 2011. At: www.tga.gov.au/equivalence-herbal-extracts-complementary-medicines
- Heinrich M. Quality and safety of herbal medical products: regulation and the need for quality assurance along the value chains. *Br J Clin Pharmacol* 2015;80(1):62–6.
- Byard RW, Musgrave I, Maker G, et al. What risks do herbal products pose to the Australian community?. *Med J Aust* 2017;206(2):86–90.
- Braun L, Cohen M. Herbs and natural supplements: an evidence-based guide. 4th edn. Chatswood: Elsevier; 2015.
- Royal Pharmaceutical Society of Great Britain. Herbal medicines. 4th edn. London: Pharmaceutical Press; 2013.
- Therapeutic Goods Administration. Listed medicine presentation and labels. Canberra: TGA; 2020. At: www.tga.gov.au/resource/listed-medicine-presentation-and-labels
- Therapeutic Goods Administration. Approved names for herbal ingredients. 2020. At: www.tga.gov.au/approved-names-herbal-ingredients
- Therapeutic Goods Administration. Medicine labels: guidance on TGO 91 and TGO 92. 2021. At: www.tga.gov.au/resources/resource/guidance/medicine-labels-guidance-tgo-91-and-tgo-92
- Therapeutic Goods (Therapeutic Goods Advertising Code) Instrument 2021 (Cth).
- Therapeutic Goods Administration. Restricted and prohibited representations. 2023. At: www.tga.gov.au/how-we-regulate/advertising/restricted-and-prohibited-representations-advertising/restricted-and-prohibited-representations
- Therapeutic Goods Regulations 1990 (Cth).
- Pharmaceutical Society of Australia. Complementary medicines; position statement. 2022. At: <https://my.psa.org.au/s/article/Complementary-Medicines>
- Pharmaceutical Society of Australia. Professional practice standards. Version 6. Canberra: PSA; 2023. At: www.psa.org.au/practice-support-industry/pps
- Popattia AS, La Caze A. An ethical framework for the responsibilities of pharmacists when selling complementary medicines. *Res Social Adm Pharm* 2021;17(5):850–7.
- Pharmaceutical Society of Australia. Code of ethics for pharmacists. Canberra: PSA; 2017.
- National Health and Medical Research Council. NHMRC statement on homeopathy. Canberra: NHMRC; 2015. At: www.nhmrc.gov.au/about-us/resources/homeopathy
- Therapeutic Research Center. Natural medicines. 2023. At: <https://naturalmedicines.therapeuticresearch.com/>
- Moses G. The safety of commonly used vitamins and minerals. *Aust Prescr* 2021;44(4):119–23.
- Wooltorton E. Too much of a good thing? Toxic effects of vitamin and mineral supplements. *CMAJ* 2003;169(1):47–8.
- Kennedy M. The vitamin epidemic: what is the evidence for harm or value?. *Intern Med J* 2018;48(8):901–7.
- Therapeutic Research Center. Natural medicines: COVID-19 Advisory. 2023. At: <https://naturalmedicines.therapeuticresearch.com/tools/covid-19-advisory.aspx>
- National Center for Complementary and Integrative Health. COVID-19 and "alternative" treatments: what you need to know. 2022. At: www.nccih.nih.gov/health/covid-19-and-alternative-treatments-what-you-need-to-know
- National Institutes of Health Office of Dietary Supplements. Dietary supplements in the time of COVID-19. 2023. At: <https://ods.od.nih.gov/factsheets/COVID19-HealthProfessional>
- Therapeutic Goods Administration. Evidence guidelines. 2022. At: www.tga.gov.au/resources/resource/guidance/evidence-guidelines
- Myers SP, Cheras PA. The other side of the coin: safety of complementary and alternative medicine. *Med J Aust* 2004;181(4):222–5.
- Moses GM, McGuire TM. Drug interactions with complementary medicines. *Aust Prescr* 2010;33(6):177–80.
- Pharmaceutical Society of Australia. Medicine safety: take care. Canberra: PSA; 2019. At: www.psa.org.au/advocacy/working-for-our-profession/medicine-safety/take-care
- Memorial Sloan Kettering Cancer Center. Integrative medicine. 2023. At: www.mskcc.org/cancer-care/diagnosis-treatment/symptom-management/integrative-medicine
- National Center for Complementary and Integrative Health. Herbs at a glance. 2023. At: www.nccih.nih.gov/health/herbsataglance
- Frawley J, Adams J, Sibbritt D, et al. Prevalence and determinants of complementary and alternative medicine use during pregnancy: results from a nationally representative sample of Australian pregnant women. *Aust N Z J Obstet Gynaecol* 2013;53(4):347–52.
- Australian Government Department of Health. Clinical practice guidelines: pregnancy care. 2020. At: www.health.gov.au/resources/pregnancy-care-guidelines
- Crighton E, Coghlan ML, Farrington R, et al. Toxicological screening and DNA sequencing detects contamination and adulteration in regulated herbal medicines and supplements for diet, weight loss and cardiovascular health. *J Pharm Biomed Anal* 2019;176:112834.
- Royal Hospital for Women: MotherSafe. Herbal medicines in pregnancy and breastfeeding. 2020. At: www.sesid.health.nsw.gov.au/sites/default/files/groups/Royal_Hospital_for_Women/Mothersafe/documents/MSHerbalApril2020.pdf
- Sport Integrity Australia. Supplements in sport. At: www.sportintegrity.gov.au/what-we-do/anti-doping/supplements-sport
- Coon JT, Ernst E. *Andrographis paniculata* in the treatment of upper respiratory tract infections: a systematic review of safety and efficacy. *Planta Med* 2004;70(4):293–8.
- Hu X-Y, Wu R-H, Logue M, et al. *Andrographis paniculata* (Chuán Xīn Lián) for symptomatic relief of acute respiratory tract infections in adults and children: a systematic review and meta-analysis. *PLoS One* 2017;12(8):e0181780.
- Therapeutic Goods Administration. *Andrographis paniculata*. 2020. At: www.tga.gov.au/alert/andrographis-paniculata
- Therapeutic Goods Administration. Products containing *Andrographis paniculata*. 2015. At: www.tga.gov.au/alert/products-containing-andrographis-paniculata
- Worakunphanich W, Thavorncharoensap M, Youngkong S, et al. Safety of *Andrographis paniculata*: a systematic review and meta-analysis. *Pharmacoepidemiol Drug Saf* 2021;30(6):727–39.
- Memorial Sloan Kettering Cancer Center. About herbs, botanicals and other products. 2023. At: www.mskcc.org/cancer-care/diagnosis-treatment/symptom-management/integrative-medicine/herbs
- Williamson E, Driver S, Baxter K, eds. *Stockley's herbal medicines interactions*. 2nd edn. London: Pharmaceutical Press; 2013.

49. Gupta RC, Chang D, Nammi S, et al. Interactions between antidiabetic drugs and herbs: an overview of mechanisms of action and clinical implications. *Diabetol Metab Syndr* 2017;9(5/9).
50. Sundhani E, Lukitaningsih E, Nurrochmad A, et al. Potential pharmacokinetic and pharmacodynamic herb–drug interactions of *Andrographis paniculata* (Burm. f.) and andrographolide: a systematic review. *J Herbmed Pharmacol* 2022;11(2):154–165.
51. Ma HY, Sun DX, Cao YF, et al. Herb–drug interaction prediction based on the high specific inhibition of andrographolide derivatives towards UDP-glucuronosyltransferase (UGT) 2B7. *Toxicol Appl Pharmacol* 2014;277(1):86–94.
52. World Health Organization. WHO monographs on selected medicinal plants. Volume 2. Geneva: WHO; 2002.
53. Sahebkar A, Pirro M, Banach M, et al. Lipid-lowering activity of artichoke extracts: a systematic review and meta-analysis. *Crit Rev Food Sci Nutr* 2018;58(15):2549–56.
54. Kamel AM, Farag MA. Therapeutic potential of artichoke in the treatment of fatty liver: a systematic review and meta-analysis. *J Med Food* 2022;25(10):931–42.
55. Holtmann G, Adam B, Haag S, et al. Efficacy of artichoke leaf extract in the treatment of patients with functional dyspepsia: a six-week placebo-controlled, double-blind, multicentre trial. *Aliment Pharmacol Ther* 2003;18(11–12):1099–105.
56. Wider B, Pittler MH, Thompson-Coon J, et al. Artichoke leaf extract for treating hypercholesterolaemia. *Cochrane Database of Systematic Reviews* 2013, Issue 3.
57. European Medicines Agency. European Union herbal monograph on *Cynara cardunculus L. (syn. Cynara scolymus L.)*, folium. London: EMA; 2018. At: www.ema.europa.eu/en/medicines/herbal/cynarae-folium
58. Chen MH, May BH, Zhou IW, et al. Integrative medicine for relief of nausea and vomiting in the treatment of colorectal cancer using oxaliplatin-based chemotherapy: a systematic review and meta-analysis. *Phytother Res* 2016;30(5):741–53.
59. Lin S, An X, Guo Y, et al. Meta-analysis of astragalus-containing traditional Chinese medicine combined with chemotherapy for colorectal cancer: efficacy and safety to tumor response. *Front Oncol* 2019;9:749.
60. Tian QE, De Li H, Yan M, et al. Effects of Astragalus polysaccharides on P-glycoprotein efflux pump function and protein expression in H22 hepatoma cells in vitro. *BMC Complement Altern Med* 2012;12:94.
61. Zhou Q, Ye Z, Ruan Z, et al. Investigation on modulation of human P-gp by multiple doses of *Radix Astragali* extract granules using fexofenadine as a phenotyping probe. *J Ethnopharmacol* 2013;146(3):744–9.
62. Jiangbo Z, Xuying W, Yuping Z, et al. Effect of astragaloside IV on the embryo-fetal development of Sprague–Dawley rats and New Zealand White rabbits. *J Appl Toxicol* 2009;29(5):381–5.
63. Buckingham R, ed. *Tragacanth*. In: *Martindale: the complete drug reference*. 40th edn. London: Pharmaceutical Press. At: www.medicinescomplete.com.
64. Singh S, McGuinness MB, Anderson AJ, et al. Interventions for the management of computer vision syndrome: a systematic review and meta-analysis. *Ophthalmology* 2022;129(10):1192–215.
65. Stefanescu R, Laczko-Zold E, Osz BE, et al. An updated systematic review of *Vaccinium myrtillus* leaves: phytochemistry and pharmacology. *Pharmaceutics* 2023;15(1):16.
66. Fuchikami H, Satoh H, Tsujimoto M, et al. Effects of herbal extracts on the function of human organic anion-transporting polypeptide OATP-B. *Drug Metab Dispos* 2006;34(4):577–82.
67. Drugs and lactation database (LactMed). Bilberry. 2021. At: www.ncbi.nlm.nih.gov/books/NBK501825
68. Beer AM, Neff A. Differentiated evaluation of extract-specific evidence on *Cimicifuga racemosa*'s efficacy and safety for climacteric complaints. *Evid Based Complement Alternat Med*; 2013:860602.
69. Fritz H, Seely D, McGowan J, et al. Black cohosh and breast cancer: a systematic review. *Integr Cancer Ther* 2014;13(1):12–29.
70. Franco OH, Chowdhury R, Troup J, et al. Use of plant-based therapies and menopausal symptoms: a systematic review and meta-analysis. *JAMA* 2016;315(23):2554–63.
71. Sarri G, Pedder H, Dias S, et al. Vasomotor symptoms resulting from natural menopause: a systematic review and network meta-analysis of treatment effects from the National Institute for Health and Care Excellence guideline on menopause. *BJOG* 2017;124(10):1514–23.
72. Castelo-Branco C, Gambacciani M, Cano A, et al. Review and meta-analysis: isopropanolic black cohosh extract iCR for menopausal symptoms—an update on the evidence. *Climacteric* 2021;24(2):109–19.
73. European Medicines Agency. European Union herbal monograph on *Cimicifuga racemosa (L.) Nutt.*, rhizoma. London: EMA; 2017. At: www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-cimicifuga-racemosa-l-nutt-rhizome-revision-1_en.pdf
74. Leach MJ, Moore V. Black cohosh (*Cimicifuga* spp.) for menopausal symptoms. *Cochrane Database of Systematic Reviews* 2012, Issue 9.
75. Buckingham R, ed. *Cimicifuga*. *Martindale: The complete drug reference*; [updated May 2023]. At: www.medicinescomplete.com/#/content/martindale/12570-e7hspl=black&hspl=cohos#content%2Fmartindale%2F12570-e%2312570-a3-t
76. Therapeutic Goods Administration. Australian adverse drug reactions bulletin: volume 26, number 3. 2007. At: www.tga.gov.au/sites/default/files/aadr-0706.pdf
77. Rockwell S, Liu Y, Higgins SA. Alteration of the effects of cancer therapy agents on breast cancer cells by the herbal medicine black cohosh. *Breast Cancer Res Treat* 2005;90(3):233–9.
78. Einbond LS, Shimizu M, Nuntanakorn P, et al. Actein and a fraction of black cohosh potentiate antiproliferative effects of chemotherapy agents on human breast cancer cells. *Planta Med* 2006;72(13):1200–6.
79. Gurley BJ, Gardner SF, Hubbard MA, et al. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. *Clin Pharmacol Ther* 2005;77:415–26.
80. Gurley BJ, Swain A, Hubbard MA, et al. Clinical assessment of CYP2D6-mediated herb–drug interactions in humans: effects of milk thistle, black cohosh, goldenseal, kava kava, St. John's wort, and Echinacea. *Mol Nutr Food Res* 2008;52(7):755–63.
81. Royal Women's Hospital. Pregnancy and breastfeeding medicines guide. 2023. At: <https://thewomenspbmg.org.au>
82. Oltean H, Robbins C, van-Tulder MW, et al. Herbal medicine for low-back pain. *Cochrane Database of Systematic Reviews* 2014, Issue 12.
83. Griebeler ML, Morey-Vargas OL, Brito JP, et al. Pharmacologic interventions for painful diabetic neuropathy: an umbrella systematic review and comparative effectiveness network meta-analysis. *Ann Intern Med* 2014;161(9):639–49.
84. van Nooten F, Treur M, Pantiri K, et al. Capsaicin 8% patch versus oral neuropathic pain medications for the treatment of painful diabetic peripheral neuropathy: a systematic literature review and network meta-analysis. *Clin Ther* 2017;39(4):787–803.
85. Derry S, Rice AS, Cole P, et al. Topical capsaicin (high concentration) for chronic neuropathic pain in adults. *Cochrane Database of Systematic Reviews* 2017, Issue 1.
86. Yong YL, Tan LT, Ming LC, et al. The effectiveness and safety of topical capsaicin in postherpetic neuralgia: a systematic review and meta-analysis. *Front Pharmacol* 2016;7:538.
87. Medicines information. eMIMS cloud; 2023. At: www.emims.com.au/Australia/drug/search.
88. Medicines information. eMIMS cloud; 2023. At: www.emims.com.au/Australia/drug/search
89. Hakas JF Jr. Topical capsaicin induces cough in patient receiving ACE inhibitor. *Ann Allergy* 1990;65:322–3. (4).
90. Zhu HD, Gu N, Wang M, et al. Effects of capsaicin on rat cytochrome P450 isoforms CYP1A2, CYP2C19, and CYP3A4. *Drug Dev Ind Pharm* 2015;41(11):1824–8.
91. Han Y, Tan TMC, Lim LY. Effects of capsaicin on P-gp function and expression in Caco-2 cells. *Biochem Pharmacol* 2006;71(12):1727–34.
92. Bouraoui A, Brazier JL, Zouaghi H, et al. Theophylline pharmacokinetics and metabolism in rabbits following single and repeated administration of Capsicum fruit. *Eur J Drug Metab Pharmacokinet* 1995;20:173–8.
93. Drugs and lactation database (LactMed). Capsaicin. 2021. At: www.ncbi.nlm.nih.gov/books/NBK574071/
94. Drugs and lactation database (LactMed). Capsicum. 2021. At: www.ncbi.nlm.nih.gov/books/NBK501824/

95. Derry S, Sven-Rice A, Cole P, et al. Topical capsaicin (high concentration) for chronic neuropathic pain in adults. *Cochrane Database of Systematic Reviews* 2013, Issue 2.
96. Puig L, de-Moraqas JM. Enhancement of PUVA phototoxic effects following celery ingestion: cool broth also can burn. *Arch Dermatol* 1994;130(6):809–10.
97. Peterson S, Lampe JW, Bammler TK, et al. Apiaceous vegetable constituents inhibit human cytochrome P-450 1A2 (hCYP1A2) activity and hCYP1A2-mediated mutagenicity of aflatoxin B1. *Food Chem Toxicol* 2006;44(9):1474–84.
98. Moses G. Thyroxine interacts with celery seed tablets? *Aust Prescr* 2001;24(1):6–7.
99. Shayani Rad M, Moohebat M, Mohajeri SA. Effect of celery (*Apium graveolens*) seed extract on hypertension: a randomized, triple-blind, placebo-controlled, cross-over, clinical trial. *Phytother Res* 2022;36(7):2889–907.
100. Ottlinger B, Storr M, Malfertheiner P, et al. STW 5 (Iberogast): a safe and effective standard in the treatment of functional gastrointestinal disorders. *Wien Med Wochenschr* 2013;163(3–4):65–72.
101. Baez G, Vargas C, Arancibia M, et al. Non-Chinese herbal medicines for functional dyspepsia. *Cochrane Database of Systematic Reviews* 2023, Issue 6.
102. Melzer J, Rösch W, Reichling J, et al. Meta-analysis: phytotherapy of functional dyspepsia with the herbal drug preparation STW 5 (Iberogast). *Aliment Pharmacol Ther* 2004;20(11–12):1279–87.
103. Functional heartburn and functional dyspepsia. Therapeutic guidelines; [updated Aug 2022]. At: https://tgldcdp.tg.org.au/viewTopic?etgAccess=true&guidelinePage=Gastrointestinal&topicfile=c_GIG_Gastro-oesophageal-reflux-in-adultstopic_1&guidelinename=auto§ionId=c_GIG_Functional-heartburn-and-functional-dyspepsiatopic_4#c_GIG_Functional-heartburn-and-functional-dyspepsiatopic_4
104. Madisch A, Holtmann G, Plein K, et al. Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multi-centre trial. *Aliment Pharmacol Ther* 2004;19(3):271–9.
105. Irritable bowel syndrome in adults. Therapeutic guidelines; [updated Aug 2022]. At: https://tgldcdp.tg.org.au/viewTopic?etgAccess=true&guidelinePage=Gastrointestinal&topicfile=c_GIG_Gastro-oesophageal-reflux-in-adultstopic_1&guidelinename=auto§ionId=c_GIG_Irritable-bowel-syndrome-in-adultstopic_18#c_GIG_Irritable-bowel-syndrome-in-adultstopic_18
106. Segal R, Pilote L. Warfarin interaction with *Matricaria chamomilla*. *CMAJ* 2006;174(9):1281–2.
107. Kassi E, Papoutsis Z, Fokialakis N, et al. Greek plant extracts exhibit selective estrogen receptor modulator (SERM)-like properties. *J Agric Food Chem* 2004;52(23):6956–61.
108. Sridharan S, Archer N, Manning N. Premature constriction of the fetal ductus arteriosus following the maternal consumption of camomile herbal tea. *Ultrasound Obstet Gynecol* 2009;34(3):358–9.
109. Buckingham R, ed. *Agnus castus*. Martindale: The complete drug reference; [updated Oct 2022]. At: www.medicinescomplete.com/#/
110. Ooi SL, Watts S, McClean R, et al. *Vitex agnus-castus* for the treatment of cyclic mastalgia: a systematic review and meta-analysis. *J Womens Health (Larchmt)* 2020;29(2):262–78.
111. van Die MD, Burger HG, Teede HJ, et al. *Vitex agnus-castus* extracts for female reproductive disorders: a systematic review of clinical trials. *Planta Med* 2013;79(7):562–75.
112. Verkaik S, Kamperman AM, van Westrhenen R, et al. The treatment of premenstrual syndrome with preparations of *Vitex agnus castus*: a systematic review and meta-analysis. *Am J Obstet Gynecol* 2017;217(2):150–66.
113. Csupor D, Lantos T, Hegyi P, et al. *Vitex agnus-castus* in premenstrual syndrome: a meta-analysis of double-blind randomised controlled trials. *Complement Ther Med* 2019;47:102190.
114. Braun L, Cohen M. *Herbs and natural supplements: an evidence-based guide*. 3rd edn. Sydney: Elsevier; 2010.
115. Therapeutic Goods Administration. *Vitex agnus-castus*. 2019. At: www.tga.gov.au/alert/vitex-agnus-castus
116. Drugs and Lactation Database (LactMed). *Chasteberry*. 2022. At: www.ncbi.nlm.nih.gov/books/NBK501807/
117. Dugoua JJ, Seely D, Perri D, et al. Safety and efficacy of chastetree (*Vitex agnus-castus*) during pregnancy and lactation. *Can J Clin Pharmacol* 2008;15(1):e74–9.
118. Najib FS, Poordast T, Mahmudi MS, et al. Does *Vitex agnus-castus* L. have deleterious effect on fertility and pregnancy outcome? An experimental study on rats for prediction of its safety. *J Pharmacopuncture* 2022;25(2):106–13.
119. Banach M, Serban C, Ursioni S, et al. Statin therapy and plasma coenzyme Q10 concentrations: a systematic review and meta-analysis of placebo-controlled trials. *Pharmacol Res* 2015;99:329–36.
120. Bank G, Kagan D, Madhavi D. Coenzyme Q10: clinical update and bioavailability. *J Evid Based Complementary Altern Med* 2011;16(2):129–37.
121. Zhang SY, Yang KL, Zeng LT, et al. Effectiveness of coenzyme Q10 supplementation for type-2 diabetes mellitus: a systematic review and meta-analysis. *Int J Endocrinol* 2018;6484839.
122. Gholnari T, Aghadavod E, Soleimani A, et al. The effects of coenzyme Q10 supplementation on glucose metabolism, lipid profiles, inflammation, and oxidative stress in patients with diabetic nephropathy: a randomized, double-blind, placebo-controlled trial. *J Am Coll Nutr* 2018;37(3):188–93.
123. Tsai IC, Hsu CW, Chang CH, et al. Effectiveness of coenzyme Q10 supplementation for reducing fatigue: a systematic review and meta-analysis of randomized controlled trials. *Front Pharmacol* 2022;13:883251.
124. Madmani ME, Yusuf Solaiman AY, Tamr Agha K, et al. Coenzyme Q10 for heart failure. *Cochrane Database of Systematic Reviews* 2014, Issue 6.
125. Lei L, Liu Y. Efficacy of coenzyme Q10 in patients with cardiac failure: a meta-analysis of clinical trials. *BMC Cardiovasc Disord* 2017;17(1):196.
126. Ho MJ, Li ECK, Wright JM. Blood pressure lowering efficacy of coenzyme Q10 for primary hypertension. *Cochrane Database of Systematic Reviews* 2016, Issue 3.
127. Sue-Ling CB, Abel WM, Sue-Ling K. Coenzyme Q10 as adjunctive therapy for cardiovascular disease and hypertension: a systematic review. *J Nutr* 2022;152(7):1666–74.
128. Parohan M, Sarraf P, Javanbakht M, et al. Effect of coenzyme Q10 supplementation on clinical features of migraine: a systematic review and dose-response meta-analysis of randomized controlled trials. *Nutr Neurosci* 2020;23(11):868–75.
129. Sazali S, Badrin S, Norhayati MN, et al. Coenzyme Q10 supplementation for prophylaxis in adult patients with migraine – a meta-analysis. *BMJ Open* 2021;15:e039358.
130. Migraine. Therapeutic guidelines; [updated Jan 2019]. At: <https://tgldcdp.tg.org.au/viewTopic?etgAccess=true&guidelinePage=Neurology&topicfile=migraine>
131. Negida A, Menshawy A, Ashal GE, et al. Coenzyme Q10 for patients with Parkinson's disease: a systematic review and meta-analysis. *CNS Neurol Disord Drug Targets* 2016;15(1):45–53.
132. Zhu ZG, Sun MX, Zhang WL, et al. The efficacy and safety of coenzyme Q10 in Parkinson's disease: a meta-analysis of randomized controlled trials. *Neurol Sci* 2017;38(2):215–24.
133. Taylor BA. Does coenzyme Q10 supplementation mitigate statin-associated muscle symptoms?. *Am J Cardiovasc Drugs* 2018;18(2):75–82.
134. Qu H, Guo M, Chai H, et al. Effects of coenzyme Q10 on statin-induced myopathy: an updated meta-analysis of randomized controlled trials. *J Am Heart Assoc* 2018;7(1):e009835.
135. Kennedy C, Koller Y, Surkova E. Effect of coenzyme Q10 on statin-associated myalgia and adherence to statin therapy: a systematic review and meta-analysis. *Atherosclerosis* 2020;299:1–8.
136. Baskaran R, Shanmugam S, Nagayya-Sriraman S, et al. The effect of coenzyme Q10 on the pharmacokinetic parameters of theophylline. *Arch Pharm Res* 2008;31(7):938–44.
137. Therapeutic Goods Administration. Complementary Medicines Evaluation Committee extracted ratified minutes, 11th meeting, 24 February. 1999. At: www.tga.gov.au/sites/default/files/cmec-minutes-11.pdf
138. Drugs and Lactation Database (LactMed). *Coenzyme Q10*. 2021. At: www.ncbi.nlm.nih.gov/books/NBK501788/
139. DiNicolantonio JJ, Bhutani J, McCarty MF, et al. Coenzyme Q10 for the treatment of heart failure: a review of the literature. *Open Heart* 2015;2(1):e000326.

140. Banach M, Serban C, Sahebkar A, et al. Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials. *Mayo Clin Proc* 2015;90(1):24–34.
141. de Llano DG, Lui H, Khoo C, et al. Some new findings regarding the antiadhesive activity of cranberry phenolic compounds and their microbial-derived metabolites against uropathogenic bacteria. *J Agric Food Chem* 2019;67(8):2166–74.
142. Samarasinghe S, Reid R, Al-Bayati M. The anti-virulence effect of cranberry active compound proanthocyanins (PACs) on expression of genes in the third-generation cephalosporin-resistant *Escherichia coli* CTX-M-15 associated with urinary tract infection. *Antimicrob Resist Infect Control* 2019;8(181).
143. Liska DJ, Kern HJ, Maki KC. Cranberries and urinary tract infections: how can the same evidence lead to conflicting advice? *Adv Nutr* 2016;7(3):498–506.
144. Durham SH, Stamm PL, Eiland LS. Cranberry products for the prophylaxis of urinary tract infections in pediatric patients. *Ann Pharmacother* 2015;49(12):1349–56.
145. Luis A, Domingues F, Pereira L, et al. Can cranberries contribute to reduce the incidence of urinary tract infections? A systematic review with meta-analysis and trial sequential analysis of clinical trials. *J Urol* 2017;198(3):614–21.
146. Fu Z, Liska D, Talan D, et al. Cranberry reduces the risk of urinary tract infection recurrence in otherwise healthy women: a systematic review and meta-analysis. *J Nutr* 2017;147(12):2282–8.
147. Valente J, Pendry BA, Galante E. Cranberry (*Vaccinium macrocarpon*) as a prophylaxis for urinary tract infections in women: a systematic review with meta-analysis. *J Herb Med* 2022;36:100602.
148. Williams G, Hahn D, Stephens JH, et al. Cranberries for preventing urinary tract infections. *Cochrane Database of Systematic Reviews* 2023, Issue 4.
149. Jepson RG, Mihaljevic L, Craig JC. Cranberries for treating urinary tract infections. *Cochrane Database of Systematic Reviews* 1998, Issue 4.
150. Dave AA, Samuel J. Suspected interaction of cranberry juice extracts and tacrolimus serum levels: a case report. *Cureus* 2016;8(5):e610.
151. Mohammed Abdul M, Jiang X, Williams KM, et al. Pharmacodynamic interaction of warfarin with cranberry but not with garlic in healthy subjects. *Br J Pharmacol* 2008;154(8):1691–700.
152. Tan CSS, Lee SWH. Warfarin and food, herbal or dietary supplement interactions: a systematic review. *Br J Clin Pharmacol* 2021;87(2):352–74.
153. Yu CP, Yang MS, Hsu PW, et al. Bidirectional influences of cranberry on the pharmacokinetics and pharmacodynamics of warfarin with mechanism elucidation. *Nutrients* 2021;13(9):3219.
154. Drugs and Lactation Database (LactMed). Cranberry. 2022. At: www.ncbi.nlm.nih.gov/books/NBK501837/
155. Davis SR, Panjari M, Stanczyk FZ. Clinical review: DHEA replacement for postmenopausal women. *J Clin Endocrinol Metab* 2011;96(6):1642–53.
156. Therapeutic Goods Administration. Personal importation scheme. 2023. At: www.tga.gov.au/personal-importation-scheme
157. Nagels HE, Rishworth JR, Siristatidis CS, et al. Androgens (dehydroepiandrosterone or testosterone) for women undergoing assisted reproduction. *Cochrane Database of Systematic Reviews* 2015, Issue 11.
158. Schwarze JE, Canales J, Crosby J, et al. DHEA use to improve likelihood of IVF/ICSI success in patients with diminished ovarian reserve: a systematic review and meta-analysis. *JBRA Assist Reprod* 2018;22(4):369–74.
159. Zhu F, Yin S, Yang B, et al. TEAS, DHEA, CoQ10, and GH for poor ovarian response undergoing IVF-ET: a systematic review and network meta-analysis. *Reprod Biol Endocrinol* 2023;21(1):64.
160. Peixoto C, Grande AJ, Mallmann MB, et al. Dehydroepiandrosterone (DHEA) for depression: a systematic review and meta-analysis. *CNS Neurol Disord Drug Targets* 2018;17(9):706–11.
161. Scheffers CS, Armstrong S, Cantineau AEP, et al. Dehydroepiandrosterone for women in the peri- or postmenopausal phase. *Cochrane Database of Systematic Reviews* 2015, Issue 1.
162. Labrie F, Archer DF, Koltun W, et al. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. *Menopause* 2018;25(11):1339–53.
163. Corrigan AB. Dehydroepiandrosterone and sport. *Med J Aust* 1999;171(4):206–8.
164. Jenkinson DM, Harbert AJ. Supplements and sports. *Am Fam Physician* 2008;78(9):1039–46.
165. Therapeutic Goods Administration. Personal importation scheme. 2015. At: www.tga.gov.au/personal-importation-scheme
166. Thompson RD, Carlson M. Liquid chromatographic determination of dehydroepiandrosterone (DHEA) in dietary supplement products. *J AOAC Int* 2000;83(4):847–57.
167. Kim C, Halter JB. Endogenous sex hormones, metabolic syndrome, and diabetes in men and women. *Curr Cardiol Rep* 2014;16(4):467.
168. Qin Y, Santos HO, Khani V, et al. Effects of dehydroepiandrosterone (DHEA) supplementation on the lipid profile: a systematic review and dose–response meta-analysis of randomized controlled trials. *Nutr Metab Cardiovasc Dis* 2020;30(9):1465–75.
169. World Anti-Doping Agency. The prohibited list. 2023. At: www.wada-ama.org/en/prohibited-list
170. Labrie F, Diamond P, Cusan L, et al. Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. *J Clin Endocrinol Metab* 1997;82(10):3498–505.
171. Brien S, Lewith GT, McGregor G. Devil's claw (*Harpagophytum procumbens*) as a treatment for osteoarthritis: a review of efficacy and safety. *J Altern Complement Med* 2006;12(10):981–93.
172. Chrubasik JE, Roufogalis BD, Chrubasik S. Evidence of effectiveness of herbal antiinflammatory drugs in the treatment of painful osteoarthritis and chronic low back pain. *Phytother Res* 2007;21(7):675–83.
173. Devil's claw root: ulcers and gastrointestinal bleeding? *Prescribe Int* 2013;22(144):296.
174. Cuspidi C, Sala C, Tadic M, et al. Systemic hypertension induced by *Harpagophytum procumbens* (devil's claw): a case report. *J Clin Hypertens (Greenwich)* 2015;17(11):908–10.
175. Carvalho RR, Donadel CD, Cortez AF, et al. Syndrome of inappropriate antidiuretic hormone secretion induced by the phytotherapy *Harpagophytum procumbens*: case report. *J Bras Nefrol* 2017;39(1):79–81.
176. Douros A, Bronder E, Andersohn F, et al. Drug-induced acute pancreatitis: results from the hospital-based Berlin case-control surveillance study of 102 cases. *Aliment Pharmacol Ther* 2013;38(7):825–34.
177. Shaw D, Leon C, Kolev S, et al. Traditional remedies and food supplements: a 5-year toxicological study (1991–1995). *Drug Saf* 1997;17(5):342–56.
178. Unger M, Frank A. Simultaneous determination of the inhibitory potency of herbal extracts on the activity of six major cytochrome P450 enzymes using liquid chromatography/mass spectrometry and automated online extraction. *Rapid Commun Mass Spectrom* 2004;18(19):2273–81.
179. Romiti N, Tramonti G, Corti A, et al. Effects of devil's claw (*Harpagophytum procumbens*) on the multidrug transporter ABCB1/P-glycoprotein. *Phytomedicine* 2009;16(12):1095–100.
180. Zielinsky P, Busato S. Prenatal effects of maternal consumption of polyphenol-rich foods in late pregnancy upon fetal ductus arteriosus. *Birth Defects Res C Embryo Today* 2013;99(4):256–74.
181. Shou C, Li J, Liu Z. Complementary and alternative medicine in the treatment of menopausal symptoms. *Chin J Integr Med* 2011;17(12):883–8.
182. Hann SK, Park YK, Im S, et al. Angelica-induced phytophotodermatitis. *Photodermatol Photoimmunol Photomed* 1991;8(2):84–5.
183. Yu C, Chai X, Yu L, et al. Identification of novel pregnane X receptor activators from traditional Chinese medicines. *J Ethnopharmacol* 2011;136(1):137–43.
184. Seviour DK, Hokkanen J, Tolonen A, et al. Rapid screening of commercially available herbal products for the inhibition of major human hepatic cytochrome P450 enzymes using the N-in-one cocktail. *Xenobiotica* 2010;40(4):245–54.
185. Drugs and Lactation Database (LactMed). Dong quai. 2021. At: www.ncbi.nlm.nih.gov/books/NBK501836
186. Karsch-Völk M, Barrett B, Kiefer D, et al. Echinacea for preventing and treating the common cold. *Cochrane Database of Systematic Reviews* 2014, Issue 2.
187. Schapowal A, Klein P, Johnston SL. Echinacea reduces the risk of recurrent respiratory tract infections and complications: a meta-analysis of randomized controlled trials. *Adv Ther* 2015;32(3):187–200.
188. David S, Cunningham R. Echinacea for the prevention and treatment of upper respiratory tract infections: a systematic review and meta-analysis. *Complement Ther Med* 2019;44:18–26.

189. Ardjomand-Woelkart K, Bauer R. Review and assessment of medicinal safety data of orally used echinacea preparations. *Planta Med* 2016;82(1–2):17–31.
190. Mullins RJ, Heddlie R. Adverse reactions associated with echinacea: the Australian experience. *Ann Allergy Asthma Immunol* 2002;88(1):42–51.
191. Gorski JC, Huang SM, Pinto A, et al. The effect of echinacea (*Echinacea purpurea* root) on cytochrome P450 activity in vivo. *Clin Pharmacol Ther* 2004;75(1):89–100.
192. Hermann R, von Richter O. Clinical evidence of herbal drugs as perpetrators of pharmacokinetic drug interactions. *Planta Med* 2012;78(13):1458–77.
193. Liu R, Tam TW, Mao J, et al. The effect of natural health products and traditional medicines on the activity of human hepatic microsomal-mediated metabolism of oseltamivir. *J Pharm Pharm Sci* 2010;13(1):43–55.
194. Qiang Z, Hauck C, McCoy JA, et al. Echinacea sanguinea and *Echinacea pallida* extracts stimulate glucuronidation and basolateral transfer of Bauer alkaloids 8 and 10 and ketone 24 and inhibit P-glycoprotein transporter in Caco-2 cells. *Planta Med* 2013;79(3–4):266–74.
195. Gurley BJ, Swain A, Williams DK, et al. Gauging the clinical significance of P-glycoprotein-mediated herb–drug interactions: comparative effects of St John's wort, echinacea, clarithromycin, and rifampin on digoxin pharmacokinetics. *Mol Nutr Food Res* 2008;52(7):772–9.
196. Organization of Teratology Information Specialists. Echinacea. 2023. At: <https://mothertobaby.org/fact-sheets/echinacea-preparations-pregnancy>
197. Heitmann K, Havnen GC, Holst L, et al. Pregnancy outcomes after prenatal exposure to echinacea: the Norwegian Mother and Child Cohort Study. *Eur J Clin Pharmacol* 2016;72(5):623–30.
198. Drugs and Lactation Database (LactMed). Echinacea. 2021. At: www.ncbi.nlm.nih.gov/books/NBK501810
199. Bamford JTM, Ray S, Musekiwa A, et al. Oral evening primrose oil and borage oil for eczema. *Cochrane Database of Systematic Reviews* 2013, Issue 4.
200. Hooper L, Al-Khudairy L, Abdelhamid A, et al. Omega-6 fats for the primary and secondary prevention of cardiovascular disease. *Cochrane Database of Systematic Reviews* 2018, Issue 11.
201. Moradi M, Niazi A, Miri HH, et al. The effect of evening primrose oil on labor induction and cervical ripening: a systematic review and meta-analysis. *Phytother Res* 2021;35(10):5375–83.
202. Shahinfar S, Abedi P, Jahanfar S, et al. The effect of evening primrose oil on cervical ripening and birth outcomes: a systematic review and meta-analysis. *Heliyon* 2023;9(2):e13414.
203. Khorshidi M, Zarezadeh M, Moghaddam OM, et al. Effect of evening primrose oil supplementation on lipid profile: a systematic review and meta-analysis of randomized clinical trials. *Phytother Res* 2020;34(10):2628–38.
204. Sarayloo K, Najmabadi K, Ghazanfarpour M. Effects of the evening primrose oil on women's mastalgia: a systematic review of randomized controlled trials. *Malaysian Journal of Nursing* 2017;9(2):28–35.
205. Mirzaee F, Fakari FR, Babakhanian M, et al. The effectiveness of herbal medicines on cyclic mastalgia: a systematic review on meta-analysis. *Rev Bras Ginecol Obstet* 2022;44(10):972–85.
206. Christelle K, Zulkifli MM, Noor NM, et al. The effects of evening-primrose oil on menopausal symptoms: a systematic review and meta-analysis of randomized controlled trials. *Curr Women's Health Rev* 2020;16(4):265–76.
207. Dante G, Facchinetti F. Herbal treatments for alleviating premenstrual symptoms: a systematic review. *J Psychosom Obstet Gynaecol* 2011;32(1):42–51.
208. Cameron M, Gagnier JJ, Chrubasik S. Herbal therapy for treating rheumatoid arthritis. *Cochrane Database of Systematic Reviews* 2011, Issue 2.
209. Jalloh MA, Gregory PJ, Hein D, et al. Dietary supplement interactions with antiretrovirals: a systematic review. *Int J STD AIDS* 2017;28(1):4–15.
210. Osman M, Badawi E. Evening primrose oil reducing serum lithium concentration. *Ther Adv Psychopharmacol* 2016;6(5):343–44.
211. Puri BK. The safety of evening primrose oil in epilepsy. *Prostaglandins Leukot Essent Fatty Acids* 2007;77(2):101–3.
212. Dove D, Johnson P. Oral evening primrose oil: its effect on length of pregnancy and selected intrapartum outcomes in low-risk nulliparous women. *J Nurse Midwifery* 1999;44(3):320–4.
213. Wedig KE, Whitsett JA. Down the primrose path: petechiae in a neonate exposed to herbal remedy for parturition. *J Pediatr* 2008;152(1):140.
214. Drugs and Lactation Database (LactMed). Evening primrose. 2021. At: www.ncbi.nlm.nih.gov/books/NBK501894
215. Wider B, Pittler MH, Ernst E. Feverfew for preventing migraine. *Cochrane Database of Systematic Reviews* 2015, Issue 4.
216. Lopresti AL, Smith SJ, Drummond PD. Herbal treatments for migraine: a systematic review of randomised-controlled studies. *Phytother Res* 2020;34(10):2493–517.
217. Johnson ES, Kadam NP, Hylands DM, et al. Efficacy of feverfew as prophylactic treatment of migraine. *Br Med J (Clin Res Ed)* 1985;291(6495):569–73.
218. Alenzi KA, Alharbi FH, Tawhari FM, et al. Alteration of coagulation test results and vaginal bleeding associated with the use of feverfew (*Tanacetum parthenium*). *J Med Cases* 2021;12(1):9–12.
219. Unger M, Frank A. Simultaneous determination of the inhibitory potency of herbal extracts on the activity of six major cytochrome P450 enzymes using liquid chromatography/mass spectrometry and automated online extraction. *Rapid Commun Mass Spectrom* 2004;18(19):2273–81.
220. Drugs and Lactation Database (LactMed). Feverfew. 2022. At: www.ncbi.nlm.nih.gov/books/NBK501861
221. Nestel P, Clifton P, Colquhoun D, et al. Indications for omega-3 long chain polyunsaturated fatty acid in the prevention and treatment of cardiovascular disease. *Heart Lung Circ* 2015;24(8):769–79.
222. Balk EM, Adams GP, Langberg V, et al. Omega-3 fatty acids and cardiovascular disease: an updated systematic review. Evidence report/technology assessment number 223. Rockville, MD: Agency for Healthcare Research and Quality (US); 2016. At: <https://effectivehealthcare.ahrq.gov/products/fatty-acids-cardiovascular-disease/research>.
223. Cholewski M, Tomczykowa M, Tomczyk M. A comprehensive review of chemistry, sources and bioavailability of omega-3 fatty acids. *Nutrients* 2018;10(11):1662.
224. Ulven SM, Holven KB. Comparison of bioavailability of krill oil versus fish oil and health effect. *Vasc Health Risk Manag* 2015;11:511–24.
225. Gunaratne AW, Makrides M, Collins CT. Maternal prenatal and/or postnatal n-3 long chain polyunsaturated fatty acids (LCPUFA) supplementation for preventing allergies in early childhood. *Cochrane Database of Systematic Reviews* 2015, Issue 7.
226. Best KP, Gold M, Kennedy D, et al. Omega-3 long-chain PUFA intake during pregnancy and allergic disease outcomes in the offspring: a systematic review and meta-analysis of observational studies and randomized controlled trials. *Am J Clin Nutr* 2016;103(1):128–43.
227. Singh M, Singh M, Jaiswal NP, et al. Prenatal fish oil supplementation for prevention of childhood asthma and allergies: a systematic review and meta-analysis. *Am J Respir Crit Care Med* 2019;199:A7472.
228. Vahdaninia M, Mackenzie H, Dean T, et al. ω-3 LCPUFA supplementation during pregnancy and risk of allergic outcomes or sensitisation in offspring: a systematic review and meta-analysis. *Ann Allergy Asthma Immunol* 2019;122(3):302–13.e2.
229. Jia Y, Huang Y, Wang H, et al. A dose–response meta-analysis of the association between the maternal omega-3 long-chain polyunsaturated fatty acids supplement and risk of asthma/wheeze in offspring. *BMC Pediatr* 2022;22(1):422.
230. Jia Y, Huang Y, Wang H, et al. Effect of prenatal omega-3 polyunsaturated fatty acid supplementation on childhood eczema: a systematic review and meta-analysis. *Int Arch Allergy Immunol* 2023;184(1):21–32.
231. Schindler T, Sinn JKH, Osborn DA. Polyunsaturated fatty acid supplementation in infancy for the prevention of allergy. *Cochrane Database of Systematic Reviews* 2016, Issue 10.
232. Zhang Y, Lin J, Zhou R, et al. Effect of omega-3 fatty acids supplementation during childhood in preventing allergic disease: a systematic review and meta-analysis. *J Asthma* 2021;58(4):523–36.
233. Su KP, Tseng PT, Lin PY, et al. Association of use of omega-3 polyunsaturated fatty acids with changes in severity of anxiety symptoms: a systematic review and meta-analysis. *JAMA Netw Open* 2018;1(5):e182327.
234. Chang JPC, Su KP, Mondelli V, et al. Omega-3 polyunsaturated fatty acids in youths with attention deficit hyperactivity disorder: a systematic review and meta-analysis of clinical trials and biological studies. *Neuropsychopharmacology* 2018;43(3):534–45.
235. Abdullah M, Jowett B, Whittaker PJ, et al. The effectiveness of omega-3 supplementation in reducing ADHD associated symptoms in children as measured by the Conners' rating scales: a systematic review of randomized controlled trials. *J Psychiatr Res* 2019;110:64–73.

236. Attention deficit hyperactivity disorder. Therapeutic guidelines; [updated Mar 2021]. At: <https://tgldcdp.tg.org.au/viewTopic?etgAccess=true&guidelinePage=Psychotropic&topicfile=attention-deficit-hyperactivity-disorder>
237. Sarris J, Ravindran A, Yatham LN, et al. Clinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytochemicals: the World Federation of Societies of Biological Psychiatry (WFSBP) and Canadian Network for Mood and Anxiety Treatments (CANMAT) Taskforce. *World J Biol Psychiatry* 2022;23(6):424–55.
238. National Heart Foundation of Australia. Dietary position statement: fish, seafood and heart healthy eating. Canberra: Heart Foundation; 2015. At: www.heartfoundation.org.au/bundles/for-professionals/nutrition-position-statements
239. Abdelhamid AS, Brown TJ, Brainard JS, et al. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. *Cochrane Database of Systematic Reviews* 2020, Issue 3.
240. Cooper RE, Tye C, Kuntzi J, et al. Omega-3 polyunsaturated fatty acid supplementation and cognition: a systematic review and meta-analysis. *J Psychopharmacol* 2015;29(7):753–63.
241. Tan ML, Ho JJ, Teh KH. Polyunsaturated fatty acids (PUFAs) for children with specific learning disorders. *Cochrane Database of Systematic Reviews* 2016, Issue 9.
242. Sydenham E, Dangour AD, Lim WS. Omega-3 fatty acid for the prevention of cognitive decline and dementia. *Cochrane Database of Systematic Reviews* 2012, Issue 6.
243. Burckhardt M, Herke M, Wustmann T, et al. Omega-3 fatty acids for the treatment of dementia. *Cochrane Database of Systematic Reviews* 2016, Issue 4.
244. Alex A, Abbott KA, McEvoy M, et al. Long-chain omega-3 polyunsaturated fatty acids and cognitive decline in non-demented adults: a systematic review and meta-analysis. *Nutr Rev* 2020;78(7):563–78.
245. Delgado-Noguera MF, Calveche JA, Bonfil Cosp X, et al. Supplementation with long chain polyunsaturated fatty acids (LCPUFA) to breastfeeding mothers for improving child growth and development. *Cochrane Database of Systematic Reviews* 2015, Issue 7.
246. Moon K, Rao SC, Schulzke SM, et al. Longchain polyunsaturated fatty acid supplementation in preterm infants. *Cochrane Database of Systematic Reviews* 2016, Issue 12.
247. Jasani B, Simmer K, Patole SK, et al. Long chain polyunsaturated fatty acid supplementation in infants born at term. *Cochrane Database of Systematic Reviews* 2017, Issue 3.
248. Gould JF, Treyvaud K, Yelland LN, et al. Seven-year follow-up of children born to women in a randomized trial of prenatal DHA supplementation. *JAMA* 2017;317(11):1173–5.
249. Shulkin M, Pimpin L, Bellinger D, et al. n-3 fatty acid supplementation in mothers, preterm infants, and term infants and childhood psychomotor and visual development: a systematic review and meta-analysis. *J Nutr* 2018;148(3):409–18.
250. Bae JH, Kim G. Systematic review and meta-analysis of omega-3-fatty acids in elderly patients with depression. *Nutr Res* 2018;50:1–9.
251. Deane KHO, Jimoh OF, Biswas P, et al. Omega-3 and polyunsaturated fat for prevention of depression and anxiety symptoms: systematic review and meta-analysis of randomised trials. *Br J Psychiatry* 2021;218(3):135–42.
252. Downie LE, Ng SM, Lindsley KB, et al. Omega-3 and omega-6 polyunsaturated fatty acids for dry eye disease. *Cochrane Database of Systematic Reviews* 2019, Issue 12.
253. Zhang X, Ritonja JA, Zhou N, et al. Omega-3 polyunsaturated fatty acids intake and blood pressure: a dose–response meta-analysis of randomized controlled trials. *J Am Heart Assoc* 2022;11(11):e025071.
254. Hill CL, March LM, Aitkin D, et al. Fish oil in knee osteoarthritis: a randomised clinical trial of low dose versus high dose. *Ann Rheum Dis* 2016;75(1):23–9.
255. Senftleber NK, Nielsen SM, Andersen JR, et al. Marine oil supplements for arthritis pain: a systematic review and meta-analysis of randomized trials. *Nutrients* 2017;9(1):42.
256. Kuszewski JC, Wong RHX, Howe PRC. Fish oil supplementation reduces osteoarthritis-specific pain in older adults with overweight/obesity. *Rheumatol Adv Pract* 2020;4(2):rkaa036.
257. Middleton P, Gomersall JC, Gould JF, et al. Omega-3 fatty acid addition during pregnancy. *Cochrane Database of Systematic Reviews* 2018, Issue 11.
258. Abdelrahman MA, Osama H, Saeed H, et al. Impact of n-3 polyunsaturated fatty acid intake in pregnancy on maternal health and birth outcomes: systematic review and meta-analysis from randomized controlled trials. *Arch Gynecol Obstet* 2023;307(1):249–62.
259. Rheumatoid arthritis. Therapeutic guidelines; [updated Mar 2017]. At: <https://tgldcdp.tg.org.au/viewTopic?etgAccess=true&guidelinePage=Rheumatology&topicfile=rheumatoid-arthritis>
260. James M, Proudman S, Cleland L. Fish oil and rheumatoid arthritis: past, present and future. *Proc Nutr Soc* 2010;69(3):316–23.
261. Miles EA, Calder PC. Influence of marine n-3 polyunsaturated fatty acids on immune function and a systematic review of their effects on clinical outcomes in rheumatoid arthritis. *Br J Nutr* 2012;107(Suppl 2):S171–84.
262. Lee YH, Bae SC, Song GG. Omega-3 polyunsaturated fatty acids and the treatment of rheumatoid arthritis: a meta-analysis. *Arch Med Res* 2012;43(5):356–62.
263. Proudman SM, James MJ, Spargo LD, et al. Fish oil in recent onset rheumatoid arthritis: a randomised, double-blind controlled trial within algorithm-based drug use. *Ann Rheum Dis* 2015;74(11):89–95.
264. Gioxari A, Kalliora AC, Marantidou F, et al. Intake of ω -3 polyunsaturated fatty acids in patients with rheumatoid arthritis: a systematic review and meta-analysis. *Nutrition* 2018;45:114–24.e4.
265. Sigaux J, Mathieu S, Nguyen Y, et al. Impact of type and dose of oral polyunsaturated fatty acid supplementation on disease activity in inflammatory rheumatic diseases: a systematic literature review and meta-analysis. *Arthritis Res Ther* 2022;24(1):100.
266. Rheumatoid arthritis. Therapeutic guidelines; [updated Mar 2017]. At: <https://tgldcdp.tg.org.au/viewTopic?etgAccess=true&guidelinePage=Rheumatology&topicfile=rheumatoid-arthritis>
267. Principles of analgesic and anti-inflammatory drug use for musculoskeletal conditions in adults. Therapeutic guidelines; [updated Aug 2022]. At: <https://tgldcdp.tg.org.au/viewTopic?etgAccess=true&guidelinePage=Rheumatology&topicfile=principles-analgesic-and-anti-inflammatory-drug-use-musculoskeletal-conditions-in-adults>
268. Cleland LG, James MJ, Proudman SM. Fish oil: what the prescriber needs to know. *Arthritis Res Ther* 2006;8(1):202.
269. Chang CH, Tseng PT, Chen NY, et al. Safety and tolerability of prescription omega-3 fatty acids: a systematic review and meta-analysis of randomized controlled trials. *Prostaglandins Leukot Essent Fatty Acids* 2018;129:1–12.
270. Kow CS, Doi SAR, Hasan SS. The coincidence of increased risk of atrial fibrillation in randomized control trials of omega-3 fatty acids: a meta-analysis. *Expert Rev Clin Pharmacol* 2021;14(6):773–5.
271. Gencer B, Djousse L, Al-Ramady OT, et al. Effect of long-term marine ω -3 fatty acids supplementation on the risk of atrial fibrillation in randomized controlled trials of cardiovascular outcomes: a systematic review and meta-analysis. *Circulation* 2021;144(25):1981–90.
272. Therapeutic Goods Administration. Fish oil – natural. 2012. At: www.tga.gov.au/compositional-guideline/fish-oil-natural
273. Begtrup KM, Krag AE, Hvas AM. No impact of fish oil supplements on bleeding risk: a systematic review. *Dan Med J* 2017;64(5):A5366.
274. Baxter K, Preston CL, eds. Stockley's drug interactions. London: Royal Pharmaceutical Society; 2023.
275. Akedo I, Ishikawa H, Nakamura T, et al. Three cases with familial adenomatous polyposis diagnosed as having malignant lesions in the course of a long-term trial using docosahexanoic acid (DHA)-concentrated fish oil capsules. *Jpn J Clin Oncol* 1998;28(12):762–5.
276. Kelley DS, Rudolph IL. Effect of individual fatty acids of omega-6 and omega-3 type on human immune status and role of eicosanoids. *Nutrition* 2000;16(2):143–5.
277. World Health Organization. Marine oil supplementation to improve pregnancy outcomes. 2011. At: www.who.int/tools/elena/bbc/fish-oil-pregnancy
278. Food Standards Australia New Zealand. Pregnancy and healthy eating. 2024. At: www.foodstandards.gov.au/consumer/nutrition/pregnancy/pregnancy-and-healthy-eating
279. Royal Hospital for Women: MotherSafe. Omega-3 fats in pregnancy and breastfeeding. 2019. At: www.seslhd.health.nsw.gov.au/sites/default/files/groups/Royal_Hospital_for_Women/Mothersafe/documents/omega3updateaug19.pdf

280. National Heart Foundation of Australia. Fish and omega-3: questions and answers for health professionals. Canberra: Heart Foundation; 2015. At: www.heartfoundation.org.au/getmedia/741bf352b-1746-48f4-806a-30f55fddfad2/Health_Professional_QA_Fish_Omega3_Cardiovascular_Health.pdf
281. National Heart Foundation of Australia. Dietary position statement: dietary fat and heart healthy eating. Canberra: Heart Foundation; 2020. At: www.heartfoundation.org.au/bundles/for-professionals/nutrition-position-statements
282. Lipid modification. Therapeutic guidelines; [updated Jun 2023]. At: https://tgldcdp.tg.org.au/viewTopic?etgAccess=true&guidelinePage=Cardiovascular&topicfile=c_CVG_Lipid-modificationtopic_1&guidelinename=auto§ionId=c_CVG_Lipid-modificationtopic_1#c_CVG_Lipid-modificationtopic_1
283. Shang A, Cao SY, Xu XY, et al. Bioactive compounds and biological functions of garlic (*Allium sativum* L.). *Food* 2019;8(7):246.
284. Kim JY, Kwon O. Garlic intake and cancer risk: an analysis using the Food and Drug Administration's evidence-based review system for the scientific evaluation of health claims. *Am J Clin Nutr* 2009;89(1):257–64.
285. Li WQ, Zhang JY, Ma JL, et al. Effects of *Helicobacter pylori* treatment and vitamin and garlic supplementation on gastric cancer incidence and mortality: follow-up of a randomized intervention trial. *BMJ* 2019;366:f5016.
286. Zhou X, Qian H, Zhang D, et al. Garlic intake and the risk of colorectal cancer: a meta-analysis. *Medicine* 2020;99(1):e18575.
287. Lissiman E, Bhasale AL, Cohen M. Garlic for the common cold. *Cochrane Database of Systematic Reviews* 2014, Issue 11.
288. Wang J, Zhang X, Lan H, et al. Effect of garlic supplement in the management of type 2 diabetes mellitus (T2DM): a meta-analysis of randomized controlled trials. *Food Nutr Res* 2017;61(1):1377571.
289. Shabani E, Sayemiri K, Mohammadpour M. The effect of garlic on lipid profile and glucose parameters in diabetic patients: a systematic review and meta-analysis. *Prim Care Diabetes* 2019;13(1):28–42.
290. Chan WJJ, McLachlan AJ, Luca EJ, et al. Garlic (*Allium sativum* L.) in the management of hypertension and dyslipidemia: a systematic review. *J Herb Med* 2020;19:100292.
291. Gadidala SK, Johny E, Thomas C, et al. Effect of garlic extract on markers of lipid metabolism and inflammation in coronary artery disease (CAD) patients: a systematic review and meta-analysis. *Phytother Res* 2023;37(6):2242–54.
292. Ried K. Garlic lowers blood pressure in hypertensive individuals, regulates serum cholesterol, and stimulates immunity: an updated meta-analysis and review. *J Nutr* 2016;146(2):3895–965.
293. Ried K. Garlic lowers blood pressure in hypertensive subjects, improves arterial stiffness and gut microbiota: a review and meta-analysis. *Exp Ther Med* 2020;19(2):1472–78.
294. Zadhoush R, Alavi-Naeini A, Feizi A, et al. The effect of garlic (*Allium sativum*) supplementation on the lipid parameters and blood pressure levels in women with polycystic ovary syndrome: a randomized controlled trial. *Phytother Res* 2021;35(11):6335–42.
295. Mohammad Abdul MI, Jiang X, Williams KM, et al. Pharmacodynamic interaction of warfarin with cranberry but not with garlic in healthy subjects. *Br J Pharmacol* 2008;154(8):1691–700.
296. Shi S, Klotz U. Drug interactions with herbal medicines. *Clin Pharmacokinet* 2012;51(2):77–104.
297. Shaikh SA, Tischer S, Choi EK, et al. Good for the lung but bad for the liver? Garlic-induced hepatotoxicity following liver transplantation. *J Clin Pharm Ther* 2017;42(5):646–8.
298. Cho HJ, Yoon IS. Pharmacokinetic interactions of herbs with cytochrome p450 and p-glycoprotein. *Evid Based Complement Alternat Med* 2015;2015:736431.
299. Hajda J, Rentsch KM, Gubler C, et al. Garlic extract induces intestinal P-glycoprotein, but exhibits no effect on intestinal and hepatic CYP3A4 in humans. *Eur J Pharm Sci* 2010;41(5):729–35.
300. Drugs and Lactation Database (LactMed). Garlic. 2021. At: www.ncbi.nlm.nih.gov/books/NBK501782
301. Chan WJ, McLachlan AJ, Wheate NJ, et al. An evaluation of garlic products available in Australian pharmacies: from the label to the laboratory. *J Herb Med* 2018;14:61–7.
302. Salih AK, Alwan AH, Khadim M, et al. Effect of ginger (*Zingiber officinale*) intake on human serum lipid profile: systematic review and meta-analysis. *Phytother Res* 2023;37(6):2472–83.
303. Rondanelli M, Fossari F, Vecchio V, et al. Clinical trials on pain lowering effect of ginger: a narrative review. *Phytother Res* 2020;34(11):2843–56.
304. Gurung A, Khatiwada B, Kayastha B, et al. Effectiveness of *Zingiber officinale*(ginger) compared with non-steroidal anti-inflammatory drugs and complementary therapy in primary dysmenorrhoea: a systematic review. *Clin Epidemiol Glob Health* 2022;18:101152.
305. Sutton M, Mounsey AL, Russell RG. Treatment of motion sickness. *Am Fam Physician* 2012;86(2):192–5.
306. Araya-Quintanilla F, Gutierrez-Espinoza H, Munoz-Yanez M, et al. Effectiveness of ginger on pain and function in knee osteoarthritis: a PRISMA systematic review and meta-analysis. *Pain Physician* 2020;23(2):e151–61.
307. McParlin C, O'Donnell A, Robson SC, et al. Treatments for hyperemesis gravidarum and nausea and vomiting in pregnancy: a systematic review. *JAMA* 2016;316(13):1392–1401.
308. Khorasani F, Aryan H, Sobhi A, et al. A systematic review of the efficacy of alternative medicine in the treatment of nausea and vomiting of pregnancy. *J Obstet Gynaecol* 2020;40(1):10–9.
309. Hu Y, Amoah AN, Zhang H, et al. Effect of ginger in the treatment of nausea and vomiting compared with vitamin B6 and placebo during pregnancy: a meta-analysis. *J Matern Fetal Neonatal Med* 2020;35(1):187–96.
310. Nausea and vomiting during pregnancy. Therapeutic guidelines; [updated Aug 2022]. At: <https://tgldcdp.tg.org.au/viewTopic?etgAccess=true&guidelinePage=Gastrointestinal&topicfile=nausea-vomiting>
311. Jiang X, Williams KM, Liaw WS, et al. Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. *Br J Clin Pharmacol* 2005;59(4):425–32.
312. Egashira K, Sasaki H, Higuchi S, et al. Food-drug interaction of tacrolimus with pomelo, ginger and turmeric juice in rats. *Drug Metab Pharmacokinet* 2012;27(2):242–7.
313. Revol B, Gautier-Veyret E, Arrive C, et al. Pharmacokinetic herb-drug interaction between ginger and crizotinib. *Br J Clin Pharmacol* 2020;86(9):1892–3.
314. Ghayur MN, Gilani AH. Ginger lowers blood pressure through blockade of voltage-dependent calcium channels. *J Cardiovasc Pharmacol* 2005;45(1):74–80.
315. Alam MA, Bin Jordan YA, Alzenaidy B, et al. Effect of *Hibiscus sabdariffa* and *Zingiber officinale* on pharmacokinetics and pharmacodynamics of amlodipine. *J Pharm Pharmacol* 2021;73(9):1151–60.
316. Heitmann K, Nordeng H, Holst L. Safety of ginger use in pregnancy: results from a large population-based cohort study. *Eur J Clin Pharmacol* 2013;69(2):269–77.
317. Drugs and Lactation Database (LactMed). Ginger. 2022. At: www.ncbi.nlm.nih.gov/books/NBK501786
318. Yuan Q, Wang CW, Shi J, et al. Effects of Ginkgo biloba on dementia: an overview of systematic reviews. *J Ethnopharmacol* 2017;195:1–9.
319. Thancharoen O, Limwattananon C, Waleekhachonloet O, et al. Ginkgo biloba extract (EGb761), cholinesterase inhibitors, and memantine for the treatment of mild-to-moderate Alzheimer's disease: a network meta-analysis. *Drugs Aging* 2019;36(5):435–52.
320. Li D, Ma J, Wei B, et al. Effectiveness and safety of ginkgo biloba preparations in the treatment of Alzheimer's disease: a systematic review and meta-analysis. *Front Aging Neurosci* 2023;15:1124710.
321. Nicolai SPA, Kruidenier LM, Bendermacher BLW, et al. Ginkgo biloba for intermittent claudication. *Cochrane Database of Systematic Reviews* 2013, Issue 6.
322. Magalhães PVS, Dean O, Andreaza AC, et al. Antioxidant treatments for schizophrenia. *Cochrane Database of Systematic Reviews* 2016, Issue 2.
323. Zheng W, Xiang YQ, Ng CH, et al. Extract of ginkgo biloba for tardive dyskinesia: meta-analysis of randomized controlled trials. *Pharmacopsychiatry* 2016;49(3):107–11.
324. Hilton MP, Zimmermann EF, Hunt WT. Ginkgo biloba for tinnitus. *Cochrane Database of Systematic Reviews* 2013, Issue 3.
325. Spiegel R, Kalla R, Mantokoudis G, et al. Ginkgo biloba extract EGb 761® alleviates neurosensory symptoms in patients with dementia: a meta-analysis of treatment effects on tinnitus and dizziness in randomized, placebo-controlled trials. *Clin Interv Aging* 2018;13:1121–7.

326. Sereda M, Xia J, Scutt P, et al. Ginkgo biloba for tinnitus. *Cochrane Database of Systematic Reviews* 2022, Issue 11.
327. European Medicines Agency. European Union herbal monograph on Ginkgo biloba_{L.} folium. 2015. At: www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-ginkgo-biloba-folium_en.pdf
328. Kellermann AJ, Kloft C. Is there a risk of bleeding associated with standardised Ginkgo biloba extract therapy? A systematic review and meta-analysis. *Pharmacotherapy* 2011;31(5):490–502.
329. Hamilton N, Alami Y, Allan C, et al. Ginkgo biloba-related hyponatraemia: a reminder that herbal supplements are not benign. *Intern Med J* 2019;49(11):1458–60.
330. Stoddard GJ, Archer M, Shane-McWhorter L, et al. Ginkgo and warfarin interaction in a large veterans administration population. *AMIA Annu Symp Proc* 2015;2015:1174–83.
331. Ji H, Zhang G, Yue F. Adverse event due to a likely interaction between sodium aescinate and ginkgo biloba extract: a case report. *J Clin Pharm Ther* 2017;42(2):237–8.
332. Lai SW, Chen JH, Kao WY. Acute hemolytic anemia in glucose-6-phosphate dehydrogenase deficiency complicated by Ginkgo biloba. *Acta Haematol* 2013;130(4):288–90.
333. Fan L, Mao XQ, Tao GY, et al. Effect of Schisandra chinensis extract and Ginkgo biloba extract on the pharmacokinetics of talinolol in healthy volunteers. *Xenobiotica* 2009;39(3):249–54.
334. Drugs and Lactation Database (LactMed). Ginkgo. 2021. At: www.ncbi.nlm.nih.gov/books/NBK501809
335. Sadeghian M, Rahmani S, Zendeheel M, et al. Ginseng and cancer-related fatigue: a systematic review of clinical trials. *Nutr Cancer* 2020; 73(8): 1270–81.
336. Li H, Hou T, Sun S, et al. Efficacy of ginseng oral administration and ginseng injections on cancer-related fatigue: a meta-analysis. *Medicine* 2022;101(46):e31363.
337. An X, Zhang AL, Yang AW, et al. Oral ginseng formulae for stable chronic obstructive pulmonary disease: a systematic review. *Respir Med* 2011;105(2):165–76.
338. Hernández-García D, Granado-Serrano AB, Martín-Gari M, et al. Efficacy of Panax ginseng supplementation on blood lipid profile: a meta-analysis and systematic review of clinical randomized trials. *J Ethnopharmacol* 2019;243:112090.
339. Ziaei R, Ghavami A, Ghaedi E, et al. The efficacy of ginseng supplementation on plasma lipid concentration in adults: a systematic review and meta-analysis. *Complement Ther Med* 2020;48:102239.
340. Lee HW, Choi J, Lee Y, et al. Ginseng for managing menopausal woman's health: a systematic review of double-blind, randomized, placebo-controlled trials. *Medicine (Baltimore)* 2016;95(38):e4914.
341. Lee HW, Ang L, Lee MS. Using ginseng for menopausal women's health care: a systematic review of randomized placebo-controlled trials. *Complement Ther Clin Pract* 2022;48:101615.
342. Shergis JL, Di YM, Zhang AL, et al. Therapeutic potential of Panax ginseng and ginsenosides in the treatment of chronic obstructive pulmonary disease. *Complement Ther Med* 2014;22(5):944–53.
343. European Medicines Agency. Community herbal monograph on Panax ginseng C.A.Meyer, radix. 2014. At: www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-panax-ginseng-ca-meyer-radix_en.pdf
344. Shergis JL, Zhang AL, Zhou W, et al. Panax ginseng in randomised controlled trials: a systematic review. *Phytother Res* 2013;27(7):949–65.
345. Jiang X, Williams KM, Liauw WS, et al. Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. *Br J Clin Pharmacol* 2004;57(5):592–9.
346. Dasgupta A, Tso G, Wells A. Effect of Asian ginseng, Siberian ginseng, and Indian ayurvedic medicine ashwagandha on serum digoxin measurement by Digoxin III, a new digoxin immunoassay. *J Clin Lab Anal* 2008;22(4):295–301.
347. Mateo-Carrasco H, Galvez-Contreras MC, Fernandez-Gines FD, et al. Elevated liver enzymes resulting from an interaction between raltegravir and Panax ginseng: a case report and brief review. *Drug Metabol Drug Interact* 2012;27(3):171–5.
348. Drugs and Lactation Database (LactMed). Ginseng. 2021. At: www.ncbi.nlm.nih.gov/books/NBK501814
349. Buckingham R, ed. Martindale: the complete drug reference. London: Pharmaceutical Press; 2020.
350. Koncic MZ, Tomczyk M. New insights into dietary supplements used in sport: active substances, pharmacological and side effects. *Curr Drug Targets* 2013;14(9):1079–92.
351. European Medicines Agency. Community herbal monograph on Eleutherococcus senticosus (Rupr. et Maxim.) Maxim, radix. 2014. At: www.ema.europa.eu/en/medicines/herbal/eleutherococci-radix
352. Hartz AJ, Bentler S, Noyes R, et al. Randomized controlled trial of Siberian ginseng for chronic fatigue. *Psychol Med* 2004;34(1):51–61.
353. Guo S, Liu Y, Lin Z, et al. Effects of eleutheroside B and eleutheroside E on activity of cytochrome P450 in rat liver microsomes. *BMC Complement Altern Med* 2014;14:1.
354. Drugs and Lactation Database (LactMed). Eleuthero. 2021. At: www.ncbi.nlm.nih.gov/books/NBK501806
355. Henrotin Y, Mobasheri A, Marty M. Is there any scientific evidence for the use of glucosamine in the management of human osteoarthritis? *Arthritis Res Ther* 2012;14:201.
356. Osteoarthritis. Therapeutic guidelines; [updated Mar 2017]. At: <https://tgldcdp.tg.org.au/view/Topic?etgAccess=true&guidelinePage=Rheumatology&topicfile=osteoarthritis>
357. McAlindon TE, Bannuru RR, Sullivan MC, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. *Osteoarthritis Cartilage* 2014;22(3):363–88.
358. Harrison-Muñoz S, Rojas-Briones V, Irarrázaval S. Is glucosamine effective for osteoarthritis?. *Medwave* 2017;17(Suppl1):e6867.
359. Bruyere O, Cooper C, Pelletier J, et al. A consensus statement on the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis – from evidence-based medicine to the real-life setting. *Semin Arthritis Rheum* 2016;45(4 Suppl):S3–11.
360. Liu X, Machado GC, Eyles JP, et al. Dietary supplements for treating osteoarthritis: a systematic review and meta-analysis. *Br J Sports Med* 2018;52(3):167–75.
361. Derwich M, Górski B, Amm E, et al. Oral glucosamine in the treatment of temporomandibular joint osteoarthritis: A systematic review. *Int J Mol Sci* 2023;24(5):4925.
362. Rojas-Briones V, Harrison-Muñoz S, Irarrázaval S. Is chondroitin sulfate effective for osteoarthritis?. *Medwave* 2017;17(2Suppl):e6929.
363. Meng Z, Liu J, Zhou N. Efficacy and safety of the combination of glucosamine and chondroitin for knee osteoarthritis: a systematic review and meta-analysis. *Arch Orthop Trauma Surg* 2023;143(1):409–21.
364. Cerda C, Bruguera M, Pares A. Hepatotoxicity associated with glucosamine and chondroitin sulfate in patients with chronic liver disease. *World J Gastroenterol* 2013;19(32):5381–4.
365. von Felden J, Montani M, Kessebohm K, et al. Drug-induced acute liver injury mimicking autoimmune hepatitis after intake of dietary supplements containing glucosamine and chondroitin sulfate. *Int J Clin Pharmacol Ther* 2013;51(3):219–23.
366. Hoban C, Byard R, Musgrave I. Hypersensitive adverse drug reactions to glucosamine and chondroitin preparations in Australia between 2000 and 2011. *Potsgrad Med J* 2020;96(1134):190–3.
367. Knudsen JF, Sokol GH. Potential glucosamine–warfarin interaction resulting in increased international normalized ratio: case report and review of the literature and MedWatch database. *Pharmacotherapy* 2008;28(4):540–8.
368. Therapeutic Goods Administration. Australian Adverse Drug Reactions Bulletin, Vol. 27, No. 1, 2008. At: www.tga.gov.au/sites/default/files/aadr-0802.pdf
369. Tallia AF, Cardone DA. Asthma exacerbation associated with glucosamine–chondroitin supplement. *J Am Board Fam Pract* 2002;15(6):481–4.
370. Esfandiari H, Pakravan M, Zakeri Z, et al. Effect of glucosamine on intraocular pressure: a randomized clinical trial. *Eye (Lond)* 2017;31(3):389–94.
371. Murphy RK, Jaccoca EH, Rice RD, et al. Glucosamine as a possible risk factor for glaucoma. *Invest Ophthalmol Vis Sci* 2009;50(13):5850.

372. Therapeutic Goods Administration. Complementary Medicines Evaluation Committee extracted ratified minutes, 60th meeting, 16 February 2007. At: www.tga.gov.au/sites/default/files/cmec-minutes-60.pdf
373. Dostrovsky NR, Towheed TE, Hudson RW, et al. The effect of glucosamine on glucose metabolism in humans: a systematic review of the literature. *Osteoarthritis Cartilage* 2011;19(4):375–80.
374. Biggee BA, Blinn CM, Nuite M, et al. Effects of oral glucosamine sulphate on serum glucose and insulin during an oral glucose tolerance test of subjects with osteoarthritis. *Ann Rheum Dis* 2007;66(2):260–62.
375. Drugs and Lactation Database (LactMed). Glucosamine. 2021. At: www.ncbi.nlm.nih.gov/books/NBK501866
376. Mandal SK, Maji AK, Mishra SK, et al. Goldenseal (*Hydrastis canadensis* L.) and its active constituents: a critical review of their efficacy and toxicological issues. *Pharmacol Res* 2020;160:105085.
377. Gurley BJ, Gardner SF, Hubbard MA, et al. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. *Clin Pharmacol Ther* 2005;77(5):415–26.
378. Gurley BJ, Swain A, Hubbard MA, et al. Clinical assessment of CYP2D6-mediated herb–drug interactions in humans: effects of milk thistle, black cohosh, goldenseal, kava kava, St. John's wort, and Echinacea. *Mol Nutr Food Res* 2008;52(7):755–63.
379. Yamaura K, Shimada M, Nakayama N, et al. Protective effects of goldenseal (*Hydrastis canadensis* L.) on acetaminophen-induced hepatotoxicity through inhibition of CYP2E1 in rats. *Pharmacognosy Res* 2011;3(4).
380. Zhang H, Wei J, Xue R, et al. Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression. *Metabolism* 2010;59(2):285–92.
381. Gurley BJ, Swain A, Barone GW, et al. Effect of goldenseal (*Hydrastis canadensis*) and kava kava (*Piper methysticum*) supplementation on digoxin pharmacokinetics in humans. *Drug Metab Dispos* 2007;35(2):240–5.
382. Drugs and Lactation Database (LactMed). Goldenseal. 2021. At: www.ncbi.nlm.nih.gov/books/NBK501866
383. Buckingham R, ed. London: Martindale: The complete drug reference. *Hydrastis*; [updated May 2023]. At: www.medicinescomplete.com/#/content/martindale/12830-z?hsp=goldenseal
384. Chong NJ, Aziz Z. A systematic review of the efficacy of *Centella asiatica* for improvement of the signs and symptoms of chronic venous insufficiency. *Evid Based Complement Alternat Med* 2013; 2013:627182.
385. Puttarak P, Dilokthornsakul P, Saokaew S, et al. Effects of *Centella asiatica* (L.) urb. on cognitive function and mood related outcomes: a systematic review and meta-analysis. *Sci Rep* 2017;7(1):10646.
386. Arribas-López E, Zand N, Ojo O, et al. A systematic review of the effect of *Centella asiatica* on wound healing. *Int J Environ Res Public Health* 2022;19(6):3266.
387. Santos G, Gasca J, Parana R, et al. Profile of herbal and dietary supplements induced liver injury in Latin America: a systematic review of published reports. *Phytother Res* 2021;34(1):6–19.
388. Pan Y, Abd-Rashid BA, Ismail Z, et al. In vitro modulatory effects of *Andrographis paniculata*, *Centella asiatica* and *Orthosiphon stamineus* on cytochrome P450 2C19 (CYP2C19). *J Ethnopharmacol* 2011;133(2):881–7.
389. Pan Y, Abd-Rashid BA, Ismail Z, et al. In vitro modulatory effects on three major human cytochrome P450 enzymes by multiple active constituents and extracts of *Centella asiatica*. *J Ethnopharmacol* 2010;130(2):275–83.
390. Jorge OA, Jorge AD. Hepatotoxicity associated with the ingestion of *Centella asiatica*. *Rev Esp Enferm Dig* 2005;97(2):115–24.
391. Dantluri S, North-Lewis P, Karthik SV. Gotu kola induced hepatotoxicity in a child – need for caution with alternative remedies. *Dig Liver Dis* 2011;43(6):500.
392. Buckingham R, ed. London: Martindale: The complete drug reference. *Centella*; [updated Aug 2023]. At: www.medicinescomplete.com/#/content/martindale/1600-d?hsp=hydrocotyle
393. Nassiri-Asl M, Hosseinzadeh H. Review of the pharmacological effects of *Vitis vinifera* (grape) and its bioactive compounds. *Phytother Res* 2009;23(9):1197–204.
394. Garavaglia J, Markoski MM, Oliveira A, et al. Grape seed oil compounds: biological and chemical actions for health. *Nutr Metab Insights* 2016;9:59–64.
395. Rabe E, Stücker M, Esperester A, et al. Efficacy and tolerability of a red-vein leaf extract in patients suffering from chronic venous insufficiency – results of a double-blind placebo-controlled study. *Eur J Vasc Endovasc Surg* 2011;41(4):540–7.
396. Asbaghi O, Nazarian B, Reiner Z, et al. The effects of grape seed extract on glycemic control, serum lipoproteins, inflammation, and body weight: a systematic review and meta-analysis of randomized controlled trials. *Phytother Res* 2020;34(2):239–53.
397. Anjom-Shoae J, Milajerdi A, Larijani B, et al. Effects of grape seed extract on dyslipidaemia: a systematic review and dose–response meta-analysis of randomised controlled trials. *Br J Nutr* 2020;124(2):121–34.
398. European Medicines Agency. European Union herbal monograph on *Vitis vinifera* L., folium. 2017. At: www.ema.europa.eu/en/medicines/herbal/vitis-viniferae-folium
399. Ward NC, Hodgson JM, Croft KD, et al. The combination of vitamin C and grape-seed polyphenols increases blood pressure: a randomized, double-blind, placebo-controlled trial. *J Hypertens* 2005;23(2):427–34.
400. Dong SX, Ping ZZ, Xiao WZ, et al. Possible enhancement of the first-pass metabolism of phenacetin by intake of grape juice in Chinese subjects. *Br J Clin Pharmacol* 1999;48(4):638–40.
401. Beecher GR. Overview of dietary flavonoids: nomenclature, occurrence and intake. *J Nutr* 2003;133(10):3248S–3254S.
402. Lorenzo JM, Munekata PES. Phenolic compounds of green tea: health benefits and technological application in food. *Asian Pac J Trop Biomed* 2016;6(8):709–19.
403. Smeriglio A, Barreca D, Bellico E, et al. Proanthocyanidins and hydrolysable tannins: occurrence, dietary intake and pharmacological effects. *Br J Pharmacol* 2017;174(11):1244–62.
404. Filippini T, Malavolti M, Borrelli F, et al. Green tea (*Camellia sinensis*) for the prevention of cancer. *Cochrane Database of Systematic Reviews* 2020, Issue 3.
405. United States Food and Drug Administration. Veregen ointment. 2006. At: www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021902s000TOC.cfm
406. Jurgens T, Whelan A, Killian L, et al. Green tea for weight loss and weight maintenance in overweight or obese adults. *Cochrane Database of Systematic Reviews* 2012, Issue 12.
407. Lin Y, Shi D, Su B, et al. The effect of green tea supplementation on obesity: a systematic review and dose–response meta-analysis of randomized controlled trials. *Phytother Res* 2020;34(10):2459–70.
408. Therapeutic Goods Administration. *Camellia sinensis* (green tea) extract. 2018. At: www.tga.gov.au/alert/camellia-sinensis-green-tea-extract
409. Oketch-Rabah HA, Roe AL, Rider CV, et al. United States Pharmacopeia (USP) comprehensive review of the hepatotoxicity of green tea extracts. *Toxicol Rep* 2020;7:386–402.
410. Taylor JR, Wilt VM. Probable antagonism of warfarin by green tea. *Ann Pharmacother* 1999;33(4):426–8.
411. Nutescu EA, Shapiro NL, Ibrahim S, et al. Warfarin and its interactions with foods, herbs and other dietary supplements. *Expert Opin Drug Saf* 2006;5(3):433–51.
412. Golden EB, Lam PY, Kadosh A, et al. Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors. *Blood* 2009;113(23):5927–37.
413. Werba JP, Misaka S, Girolli MG, et al. Update of green tea interactions with cardiovascular drugs and putative mechanisms. *J Food Drug Anal* 2018;26(2Suppl):72–7.
414. Roth M, Timmerman BN, Hagenbuch B. Interactions of green tea catechins with organic anion-transporting polypeptides. *Drug Metab Dispos* 2011;39(5):920–6.
415. Misaka S, Yatabe J, Muller F, et al. Green tea ingestion greatly reduces plasma concentrations of nadolol in healthy subjects. *Clin Pharmacol Ther* 2014;95(4):432–8.
416. Chung J, Choi D, Choi J. Effects of oral epigallocatechin gallate on the oral pharmacokinetics of verapamil in rats. *Biopharm Drug Dispos* 2009;30(2):90–3.
417. Drugs and Lactation Database (LactMed). Green tea. 2021. At: www.ncbi.nlm.nih.gov/books/NBK501847
418. McLellan TM, Caldwell JA, Liebermann HR. A review of caffeine's effects on cognitive, physical and occupational performance. *Neurosci Biobehav Rev* 2016;71:294–312.

419. Harpaz E, Tamir S, Weinstein A, et al. The effect of caffeine on energy balance. *J Basic Clin Physiol Pharmacol* 2017;28(1):1–10.
420. Gavrieli A, Karfopoulou E, Karditou E, et al. Effect of different amounts of coffee on dietary intake and appetite of normal-weight and overweight/obese individuals. *Obesity (Silver Spring)* 2013;21(6):1127–32.
421. Rodrigues CM, del Giglio A. Paullinia cupana (guarana) for chemotherapy-induced fatigue in patients with solid tumors: a meta-analysis. *Clin Onc Lett* 2018;3(1–2):53–61.
422. Konstantinos F, Heun R. The effects of guarana (Paullinia cupana) supplementation on the cognitive performance of young healthy adults: a systematic review. *Glob Psychiatry* 2019;2(2):171–82.
423. Pennay A, Lubman D, Miller P. Combining energy drinks and alcohol: a recipe for trouble? *Aust Fam Physician* 2011;40(3):104–7.
424. Lalanne L, Lutz P, Paille F. Acute impact of caffeinated alcoholic beverages on cognition: a systematic review. *Prog Neuropsychopharmacol Biol Psychiatry* 2017;76:188–94.
425. Buckingham R, ed. Martindale: The complete drug reference. Caffeine; [updated 2023 Aug]. At: www.medicinescomplete.com/#/content/martindale/621-x?hsp=caffeine
426. Vaz J, Kulkarni C, David J, et al. Influence of caffeine on pharmacokinetic profile of sodium valproate and carbamazepine in normal human volunteers. *Indian J Exp Biol* 1998;36(1):112–4.
427. Shet MS, McPhaul M, Fisher CW, et al. Metabolism of the antiandrogenic drug (flutamide) by human CYP1A2. *Drug Metab Dispos* 1997;25(11):1298–303.
428. van der Hoeven N, Visser I, Schene A, et al. Severe hypertension related to caffeinated coffee and tranlycypromine: a case report. *Ann Intern Med* 2014;160(9):657–8.
429. Lee DR, Lee J, Rota M, et al. Coffee consumption and risk of fractures: a systematic review and dose–response meta-analysis. *Bone* 2014;63:20–8.
430. Wikoff D, Welsh BT, Henderson R, et al. Systematic review of the potential adverse effects of caffeine consumption in healthy adults, pregnant women, adolescents, and children. *Food Chem Toxicol* 2017;109:585–648.
431. Bryant CM, Dowell CJ, Fairbrother G. Caffeine reduction education to improve urinary symptoms. *Br J Nurs* 2002;11(8):560–5.
432. Royal Hospital for Women: MotherSafe. Caffeine and pregnancy. 2019. At: www.seslhd.health.nsw.gov.au/sites/default/files/groups/Royal_Hospital_for_Women/Mothersafe/documents/caffeineinpregnancyaug19.pdf
433. Drugs and Lactation Database (LactMed). Caffeine. 2023. At: www.ncbi.nlm.nih.gov/books/NBK501467
434. Australian Beverages Council. What's the go with energy drinks? 2020. At: www.australianbeverages.org/energy-drinks-microsite.
435. Food Standards Australian New Zealand. Caffeine. 2019. At: www.foodstandards.gov.au/consumer/generalissues/Pages/Caffeine.aspx
436. Seifert SM, Schaechter JL, Hershoin ER, et al. Health effects of energy drinks on children, adolescents, and young adults. *Pediatrics* 2011;127(3):511–28.
437. Ruxton C. The suitability of caffeinated drinks for children: a systematic review of randomised controlled trials, observational studies and expert panel guidelines. *J Hum Nutr Diet* 2014;27(4):342–57.
438. Buckingham R, ed. Martindale: The complete drug reference. Crataegus; [updated Aug 2023]. At: www.medicinescomplete.com/#/content/martindale/5807-n?hsp=crataegus&hsp=laevigata
439. Guo R, Pittler MH, Ernst E. Hawthorn extract for treating chronic heart failure. *Cochrane Database of Systematic Reviews* 2008, Issue 1.
440. Holubarsch CJF, Colucci WS, Meinertz T, et al. The efficacy and safety of Crataegus extract WS 1442 in patients with heart failure: the SPICE trial. *Eur J Heart Fail* 2008;10(12):1255–63.
441. Zick SM, Gillespie B, Aaronson KD. The effect of Crataegus oxyacantha Special Extract WS 1442 on clinical progression in patients with mild to moderate symptoms of heart failure. *Eur J Heart Fail* 2008;10(6):587–93.
442. Holubarsch CJF, Colucci WS, Eha J. Benefit–risk assessment of Crataegus extract WS 1442: an evidence-based review. *Am J Cardiovasc Drugs* 2018;18(1):25–36.
443. Tankanow R, Tamer HR, Streetman DS, et al. Interaction study between digoxin and a preparation of hawthorn (Crataegus oxyacantha). *J Clin Pharmacol* 2003;43(6):637–42.
444. Dasgupta A, Kidd L, Poindexter BJ, et al. Interference of hawthorn on serum digoxin measurements by immunoassays and pharmacodynamic interaction with digoxin. *Arch Pathol Lab Med* 2010;134(8):1188–92.
445. Drugs and Lactation Database (LactMed). Hawthorn. 2021. At: www.ncbi.nlm.nih.gov/books/NBK501831
446. Holzinger F, Chenot J. Systematic review of clinical trials assessing the effectiveness of ivy leaf (Hedera helix) for acute upper respiratory tract infections. *Evid Based Complement Alternat Med* 2011;2011:382789.
447. Schaefer A, Kehr MS, Giannetti BM, et al. A randomized, controlled, double-blind, multi-center trial to evaluate the efficacy and safety of a liquid containing ivy leaves dry extract (EA 575[®]) vs. placebo in the treatment of adults with acute cough. *Pharmazie* 2016;71(9):504–9.
448. Kardos P, Dinh QT, Fuchs KH, et al. German Respiratory Society guidelines for diagnosis and treatment of adults suffering from acute, subacute and chronic cough. *Respir Med* 2020;170:105939.
449. European Medicines Agency. European Union herbal monograph on Hedera helix L., folium. 2017. At: www.ema.europa.eu/en/medicines/herbal/hederae-helicis-folium
450. Fazio S, Pouso J, Dolinsky D, et al. Tolerance, safety and efficacy of Hedera helix extract in inflammatory bronchial diseases under clinical practice conditions: a prospective, open, multicentre postmarketing study in 9657 patients. *Phytomedicine* 2009;16(1):17–24.
451. Rehman SU, Kim IS, Choi MS, et al. Time-dependent inhibition of CYP2C8 and CYP2C19 by Hedera helix extracts, a traditional respiratory herbal medicine. *Molecules* 2017;22(7):1241.
452. Lang C, Röttger-Lüer P, Staiger C. A valuable option for the treatment of respiratory diseases: review on the clinical evidence of the ivy leaves dry extract EA 575[®]. *Planta Med* 2015;81(12–13):968–74.
453. Sarris J, Moylan S, Camfield DA, et al. Complementary medicine, exercise, meditation, diet, and lifestyle modification for anxiety disorders: a review of current evidence. *Evid Based Complement Alternat Med* 2012;2012:809653.
454. Sarris J, Stough C, Bousman CA, et al. Kava in the treatment of generalized anxiety disorder: a double-blind, randomized, placebo-controlled study. *J Clin Psychopharmacol* 2013;33(5):643–8.
455. Sarris J, Stough C, Teschke R, et al. Kava for the treatment of generalized anxiety disorder RCT: analysis of adverse reactions, liver function, addiction, and sexual effects. *Phytother Res* 2013;27(11):1723–8.
456. European Medicines Agency. Assessment report on Piper methysticum G. Forst., rhizoma. 2017. At: www.ema.europa.eu/en/medicines/herbal/piperis-methystici-rhizoma
457. Therapeutic Goods Administration. Poisons standard. 2023. At: www.tga.gov.au/how-we-regulate/ingredients-and-scheduling-medicines-and-chemicals/poisons-standard-and-scheduling-medicines-and-chemicals/poisons-standard-susmp
458. Food Standards Australia New Zealand. Kava: a human health risk assessment. Technical report series no. 30. Canberra: FSANZ; 2005.
459. Wainiqolo I, Kool B, Nosa V, et al. Is driving under the influence of kava associated with motor vehicle crashes? A systematic review of the epidemiological literature. *Aust N Z J Public Health* 2015;39(5):495–9.
460. Pittler MH, Ernst E. Kava extract versus placebo for treating anxiety. *Cochrane Database of Systematic Reviews* 2003, Issue 1.
461. Teschke R, Sarris J, Schweitzer I. Kava hepatotoxicity in traditional and modern use: the presumed Pacific kava paradox hypothesis revisited. *Br J Clin Pharmacol* 2012;73(2):170–4.
462. Martindale: The complete drug reference. Seaweeds, kelps, and wracks; [updated 2023 May]. At: www.medicinescomplete.com/#/content/martindale/22474-b?hsp=kelp
463. European Medicines Agency. Assessment report on Fucus vesiculosus L., thallus. 2014. At: www.ema.europa.eu/en/medicines/herbal/fucus
464. Leung AM, Braverman LE. Iodine-induced thyroid dysfunction. *Curr Opin Endocrinol Diabetes Obes* 2012;19(5):414–9.
465. Mathew L, Burney M, Gaikwad A, et al. Preclinical evaluation of safety of fucoidan extracts from Undaria pinnatifida and Fucus vesiculosus for use in cancer treatment. *Integr Cancer Ther* 2017;16(4):572–84.
466. Drugs and Lactation Database (LactMed). Seaweed. 2021. At: www.ncbi.nlm.nih.gov/books/NBK501850
467. Spinks EA, Fenwick GR. The determination of glycyrrhizin in selected UK liquorice products. *Food Addit Contam* 1990;7(6):769–78.

468. Martindale: The complete drug reference. Licorice; [updated Aug 2023]. At: www.medicinescomplete.com/#/content/martindale/2021-1?hsp=licorice
469. Martindale: The complete drug reference. St John's Wort; [updated Aug 2023]. At: www.medicinescomplete.com/#/content/martindale/314-s
470. Strandberg TE, Andersson S, Järvenpää A, et al. Preterm birth and licorice consumption during pregnancy. *Am J Epidemiol* 2002;156(9):803–5.
471. Drugs and Lactation Database (LactMed). Licorice. 2021. At: www.ncbi.nlm.nih.gov/books/NBK501840
472. Griffith RS, DeLong DC, Nelson JD. Relation of arginine–lysine antagonism to herpes simplex growth in tissue culture. *Chemotherapy* 1981;27(3):209–13.
473. Chi C, Wang S, Delamere FM, et al. Interventions for prevention of herpes simplex labialis (cold sores on the lips). *Cochrane Database of Systematic Reviews* 2015, Issue 8.
474. Lo JC, Chertow GM, Renke H, et al. Fanconi's syndrome and tubulointerstitial nephritis in association with L-lysine ingestion. *Am J Kidney Dis* 1996;28(4):614–17.
475. Civitelli R, Villareal DT, Agnusdei D, et al. Dietary L-lysine and calcium metabolism in humans. *Nutrition* 1992;8(6):400–5.
476. Martindale: The complete drug reference. Milk thistle; [updated Aug 2023]. At: www.medicinescomplete.com/#/content/martindale/18429-p?hsp=milk%20thistle
477. Voroneanu L, Nistor I, Dumea R, et al. Silymarin in type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. *J Diabetes Res* 2016;2016:5147468.
478. de Avelar CR, Pereira EM, de Farias Costa PR, et al. Effect of silymarin on biochemical indicators in patients with liver disease: systematic review with meta-analysis. *World J Gastroenterol* 2017;23(27):5004–17.
479. Tao L, Qu X, Zhang Y, et al. Prophylactic therapy of silymarin (milk thistle) on antituberculosis drug-induced liver injury: a meta-analysis of randomized controlled trials. *Can J Gastroenterol Hepatol* 2019;2019:3192351.
480. Gurley B, Hubbard MA, Williams DK, et al. Assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: comparison of a milk thistle and black cohosh product to rifampin and clarithromycin. *J Clin Pharmacol* 2006;46(2):201–13.
481. Kawaguchi-Suzuki M, Frye RF, Zhu H, et al. The effects of milk thistle (Silybum marianum) on human cytochrome P450 activity. *Drug Metab Dispos* 2014;42(10):1611–16.
482. Jiao Z, Shi X, Li Z, et al. Population pharmacokinetics of sirolimus in de novo Chinese adult renal transplant patients. *Br J Clin Pharmacol* 2009;68(1):47–60.
483. Aboras SI, Korany MA, El-Yazbi AF, et al. In-depth investigation of the silymarin effect on the pharmacokinetic parameters of sofosbuvir, GS-331007 and ledipasvir in rat plasma using LC-MS. *Biomed Chromatogr* 2022;36(9):e5427.
484. Drugs and Lactation Database (LactMed). Milk thistle. 2023. At: www.ncbi.nlm.nih.gov/books/NBK501771
485. Lockyer S, Rowland I, Spencer JPE, et al. Impact of phenolic-rich olive leaf extract on blood pressure, plasma lipids and inflammatory markers: a randomised controlled trial. *Eur J Nutr* 2017;56:1421–32.
486. Widmer RJ, Flammer AJ, Lerman LO, et al. The Mediterranean diet, its components, and cardiovascular disease. *Am J Med* 2015;128(3):229–38.
487. Susalit E, Agus N, Effendi I, et al. Olive (*Olea europaea*) leaf extract effective in patients with stage-1 hypertension: comparison with captopril. *Phytomedicine* 2011;18(4):251–8.
488. Razmpoosh E, Abdollahi S, Mousavirad M, et al. The effects of olive leaf extract on cardiovascular risk factors in the general adult population: a systematic review and meta-analysis of randomized controlled trials. *Diabetol Metab Syndr* 2022;14(1):151.
489. Timmer A, Günther J, Motschall E, et al. Pelargonium sidoides extract for treating acute respiratory tract infections. *Cochrane Database of Systematic Reviews* 2013, Issue 10.
490. Wagner L, Cramer H, Klose P, et al. Herbal medicine for cough: a systematic review and meta-analysis. *Forsch Komplementmed* 2015;22(6):359–68.
491. Careddu D, Pettenazzo A. Pelargonium sidoides extract EPs 7630: a review of its clinical efficacy and safety for treating acute respiratory tract infections in children. *Int J Gen Med* 2018;11:91–8.
492. Blackmores Institute. Pelargonium (*Pelargonium sidoides*). At: www.blackmoresinstitute.org/interactions/pelargonium
493. Martindale: The complete drug reference. Peppermint leaf; [updated Aug 2023]. At: www.medicinescomplete.com/#/content/martindale/4690-t?hsp=peppermint%4691-x
494. Martindale: The complete drug reference. Menthol; [updated Aug 2023]. At: www.medicinescomplete.com/#/content/martindale/266-k?hsp=menthol
495. Hawrelak JA, Wohlmuth H, Pattinson M, et al. Western herbal medicines in the treatment of irritable bowel syndrome: a systematic review and meta-analysis. *Complement Ther Med* 2020;48:102233.
496. Ingrosso MR, Ianrio G, Nee J, et al. Systematic review and meta-analysis: efficacy of peppermint oil in irritable bowel syndrome. *Aliment Pharmacol Ther* 2022;56(6):932–41.
497. European Medicines Agency. European Union herbal monograph on *Mentha x piperital*L., *aetheroleum*. 2020. At: www.ema.europa.eu/en/medicines/herbal/menthae-piperitae-aetheroleum
498. Therapeutic Goods Administration. ARGOM appendix 5: guidelines on OTC applications for specific substances. 2012. At: www.tga.gov.au/publication/argom-appendix-5-guidelines-otc-applications-specific-substances
499. Wachter VJ, Wong S, Wong HT. Peppermint oil enhances cyclosporine oral bioavailability in rats: comparison with D-alpha-tocopheryl poly(ethylene glycol 1000) succinate (TPGS) and ketoconazole. *J Pharm Sci* 2002;91(1):77–90.
500. Drugs and Lactation Database (LactMed). Peppermint. 2023. At: www.ncbi.nlm.nih.gov/books/NBK501851
501. Guamer F, Sanders ME, Szajewska H, et al. World Gastroenterology Organisation global guidelines: probiotics and prebiotics. 2023. At: www.worldgastroenterology.org/guidelines/probiotics-and-prebiotics/probiotics-and-prebiotics-english
502. Su GL, Ko CW, Berck P, et al. AGA clinical practice guidelines on the role of probiotics in the management of gastrointestinal disorders. *Gastroenterology* 2020;159(2):697–705.
503. McFarland LV, Evans CT, Goldstein EJC. Strain-specificity and disease-specificity of probiotic efficacy: a systematic review and meta-analysis. *Front Med (Lausanne)* 2018;5:124.
504. Newlove-Delgado TV, Martin AE, Abbott RA, et al. Dietary interventions for recurrent abdominal pain in childhood. *Cochrane Database of Systematic Reviews* 2017, Issue 3.
505. Szajewska H, Berni Canani R, Domellöf M, et al. Probiotics for the management of pediatric gastrointestinal disorders: position paper of the ESPGHAN Special Interest Group on Gut Microbiota and Modifications. *J Pediatr Gastroenterol Nutr* 2023;76(2):232–47.
506. Other supportive therapy and considerations for acute gastroenteritis. Therapeutic guidelines; [updated Aug 2022]. At: https://tgidcdp.tg.org.au/viewTopic?etgAccess=true&guidelinePage=Gastrointestinal&topicId=c_GIG_Gastro-oesophageal-reflux-in-adultopic_1&guidelinename=aut_o§ionId=c_GIG_Other-supportive-therapy-and-considerations-for-acute-gastroenteritopic_2#c_GIG_Other-supportive-therapy-and-considerations-for-acute-gastroenteritopic_2
507. Vandenplas Y. Probiotics and prebiotics in infectious gastroenteritis. *Best Pract Res Clin Gastroenterol* 2016;30(1):49–53.
508. Li Y, Xu H, Ye JZ, et al. Efficacy of *Lactobacillus rhamnosus* GG in treatment of acute pediatric diarrhea: a systematic review with meta-analysis. *World J Gastroenterol* 2019;25(33):4999–5016.
509. Patro-Golab B, Szajewska H. Systematic review with meta-analysis: *Lactobacillus reuteri* DSM 17938 for treating acute gastroenteritis in children. An update. *Nutrients* 2019;11(11):2762.
510. Szajewska H, Kolodziej M, Gieruszczak-Bialek D, et al. Systematic review with meta-analysis: *Lactobacillus rhamnosus* GG for treating acute gastroenteritis in children – a 2019 update. *Aliment Pharmacol Ther* 2019;49(11):1376–84.
511. Szajewska H, Kolodziej M, Zalewski B. Systematic review with meta-analysis: *Saccharomyces boulardii* for treating acute gastroenteritis in children – a 2020 update. *Aliment Pharmacol Ther* 2020;51(7):678–88.
512. Yang B, Lu P, Li M, et al. A meta-analysis of the effects of probiotics and synbiotics in children with acute diarrhea. *Medicine* 2019;98(37):e16618.
513. McFarland L, Goh S. Are probiotics and prebiotics effective in the prevention of travellers' diarrhea: a systematic review and meta-analysis. *Travel Med Infect Dis* 2019;27:11–19.
514. Fiocchi A, Pawankar R, Cuello-Garcia C, et al. World Allergy Organization – McMaster University guidelines for allergic disease prevention (GLAD–P): probiotics. *World Allergy Organ J* 2015;8(1):4.

515. Amalia N, Orchard D, Francis K, et al. Systematic review and meta-analysis on the use of probiotic supplementation in pregnant mother, breastfeeding mother and infant for the prevention of atopic dermatitis in children. *Australas J Dermatol* 2020;61(2):e158–73.
516. Makrgeorgou A, Leonardi-Bee J, Bath-Hextall FJ, et al. Probiotics for treating eczema. *Cochrane Database of Systematic Reviews* 2018, Issue 11.
517. Tan-Lim CSC, Esteban-Ipac NAR, Mantaring JBV, et al. Comparative effectiveness of probiotic strains for the treatment of pediatric atopic dermatitis: a systematic review and network meta-analysis. *Pediatr Allergy Immunol* 2021;32(1):124–36.
518. Rondanelli M, Faliva MA, Perna S, et al. Using probiotics in clinical practice: where are we now? A review of existing meta-analyses. *Gut Microbes* 2017;8(6):521–43.
519. Guvenç IA, Muluk NB, Mutlu FS, et al. Do probiotics have a role in the treatment of allergic rhinitis? A comprehensive systematic review and meta analysis. *Am J Rhinol Allergy* 2016;30(5):157–75.
520. Hsiao K, Ponsonby A, Axelrad C, et al. Long-term clinical and immunological effects of probiotic and peanut oral immunotherapy after treatment cessation: 4-year follow-up of a randomised, double-blind, placebo-controlled trial. *Lancet Child Adolesc Health* 2017;1(2):97–105.
521. Tan-Lim CSC, Esteban-Ipac NAR. Probiotics as treatment for food allergies among pediatric patients: a meta-analysis. *World Allergy Organ J* 2018;11:25.
522. Campos dos Santos S, Konstantyner T, Cocco RR. Effects of probiotics in the treatment of food hypersensitivity in children: a systematic review. *Allergol Immunopathol (Madr)* 2020;48(1):95–104.
523. Sodrè CS, Vieira MS, Estefan JL, et al. The effect of probiotics on the clinical status of adult patients with atopic dermatitis: a systematic review. *Eur J Med Res* 2022;27(94).
524. Uwaezuoke SN, Ayuk AC, Eze JN, et al. Postnatal probiotic supplementation can prevent and optimize treatment of childhood asthma and atopic disorders: a systematic review of randomized controlled trials. *Front Pediatr* 2022;10:956141.
525. Acute infectious diarrhoea. Therapeutic guidelines; [updated Aug 2022]. At: <https://tgldcdp.tg.org.au/viewTopic?etgAccess=true&guidelinePage=Antibiotic&topicfile=acute-gastroenteritis>
526. Goldenberg JZ, Yap C, Lytvyn L, et al. Probiotics for the prevention of *Clostridium difficile*-associated diarrhea in adults and children. *Cochrane Database of Systematic Reviews* 2017, Issue 12.
527. Guo Q, Goldenberg JZ, Humphrey C, et al. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. *Cochrane Database of Systematic Reviews* 2019, Issue 4.
528. Zhang L, Zeng X, Guo D, et al. Early use of probiotics might prevent antibiotic-associated diarrhea in elderly (>65 years): a systematic review and meta-analysis. *BMC Geriatr* 2022;22:526.
529. Derwa Y, Gracie DJ, Hamlin PJ, et al. Systematic review with meta-analysis: the efficacy of probiotics in inflammatory bowel disease. *Aliment Pharmacol Ther* 2017;46(4):389–400.
530. Limketkai BN, Akobeng AK, Gordon M, et al. Probiotics for induction of remission in Crohn's disease. *Cochrane Database of Systematic Reviews* 2020, Issue 7.
531. Crohn disease in adults. Therapeutic guidelines; [updated Aug 2022]. At: https://tgldcdp.tg.org.au/viewTopic?etgAccess=true&guidelinePage=Gastrointestinal&topicfile=c_GIG_Gastro-oesophageal-reflux-in-adultstopic_1&guidelinename=auto§ionId=c_GIG_Crohn-disease-in-adultstopic_2#c_GIG_Crohn-disease-in-adultstopic_2
532. Coffey MJ, Garg M, Homaira N, et al. Probiotics for people with cystic fibrosis. *Cochrane Database of Systematic Reviews* 2020, Issue 1.
533. Schwenger EM, Tejani AM, Loewen PS. Probiotics for preventing urinary tract infections in adults and children. *Cochrane Database of Systematic Reviews* 2015, Issue 12.
534. Xie HY, Feng D, Wei DM, et al. Probiotics for vulvovaginal candidiasis in non-pregnant women. *Cochrane Database of Systematic Reviews* 2017, Issue 11.
535. Wang Z, He Y, Zheng Y. Probiotics for the treatment of bacterial vaginosis: a meta-analysis. *Int J Environ Res Public Health* 2019;16(20):3859.
536. Dryl R, Szajewska H. Probiotics for management of infantile colic: a systematic review of randomized controlled trials. *Arch Med Sci* 2018;14(5):1137–43.
537. Sung V, D'Amico F, Cabana MD, et al. *Lactobacillus reuteri* to treat infant colic: a meta-analysis. *Paediatrics* 2018;141(1):e20171811.
538. Ong TG, Gordon M, Banks SSC, et al. Probiotics to prevent infantile colic. *Cochrane Database of Systematic Reviews* 2019, Issue 3.
539. Ellwood J, Draper-Rodi J, Carnes D. Comparison of common interventions for the treatment of infantile colic: a systematic review of reviews and guidelines. *BMJ Open* 2020;10(2):e035405.
540. Braegger C, Chmielewska A, Decsi T, et al. Supplementation of infant formula with probiotics and/or prebiotics: a systematic review and comment by the ESPGHAN committee on nutrition. *J Pediatr Gastroenterol Nutr* 2011;52(2):238–50.
541. Martin CR, Ling P, Blackburn GL. Review of infant feeding: key features of breast milk and infant formula. *Nutrients* 2016;8(5):279.
542. National Health and Medical Research Council. Infant feeding guidelines: information for health workers. Canberra: NHMRC; 2012. At: www.nhmrc.gov.au/guidelines-publications/n56
543. Indrio F, Gutierrez Castellon P, Vandenplas Y, et al. Health effects of infant formula supplemented with probiotics or synbiotics in infants and toddlers: systematic review with network meta-analysis. *Nutrients* 2022;14(23):5157.
544. Guarner F, Sanders ME, Eliakim R, et al. World Gastroenterology Organisation global guidelines: probiotics and prebiotics. WGO; 2017.
545. Kaur L, Gordon M, Baines PA, et al. Probiotics for induction of remission in ulcerative colitis. *Cochrane Database of Systematic Reviews* 2020, Issue 3.
546. Iheozor-Ejiofor Z, Kaur L, Gordon M, et al. Probiotics for maintenance of remission in ulcerative colitis. *Cochrane Database of Systematic Reviews* 2020, Issue 3.
547. Ulcerative colitis in adults. Therapeutic guidelines; [updated Aug 2022]. At: https://tgldcdp.tg.org.au/viewTopic?etgAccess=true&guidelinePage=Gastrointestinal&topicfile=c_GIG_Gastro-oesophageal-reflux-in-adultstopic_1&guidelinename=auto§ionId=c_GIG_Ulcerative-colitis-in-adultstopic_2#c_GIG_Ulcerative-colitis-in-adultstopic_2
548. Hao Q, Dong BR, Wu T. Probiotics for preventing acute upper respiratory tract infections. *Cochrane Database of Systematic Reviews* 2015, Issue 2.
549. Coleman JL, Hatch-McChesney A, Small SD, et al. Orally ingested probiotics, prebiotics, and synbiotics as countermeasures for respiratory tract infections in nonelderly adults: a systematic review and meta-analysis. *Adv Nutr* 2022;13(6):2277–95.
550. Crovesy L, Ostrowski M, Ferreira DMPT, et al. Effect of *Lactobacillus* on body weight and body fat in overweight subjects: a systematic review of randomized controlled clinical trials. *Int J Obes (Lond)* 2017;41:1607–14.
551. Koutnikova H, Genser B, Monteiro-Sepulveda M, et al. Impact of bacterial probiotics on obesity, diabetes and non-alcoholic fatty liver disease related variables: a systematic review and meta-analysis of randomised controlled trials. *BMJ Open* 2019;9(3):e017995.
552. Hungin APS, Mulligan C, Pot B, et al. Systematic review: probiotics in the management of lower gastrointestinal symptoms in clinical practice – an evidence-based international guide. *Aliment Pharmacol Ther* 2013;38(8):864–86.
553. Hojsak I, Fabiano V, Pop TL, et al. Guidance on the use of probiotics in clinical practice in children with selected clinical conditions and in specific vulnerable groups. *Acta Paediatr* 2018;107(6):927–37.
554. Roy U, Jessani LG, Rudramurthy SM, et al. Seven cases of *Saccharomyces fungaemia* related to use of probiotics. *Mycoses* 2017;60(6):375–80.
555. Meini S, Laureano R, Fani L, et al. Breakthrough *Lactobacillus rhamnosus* GG bacteremia associated with probiotic use in an adult patient with severe active ulcerative colitis: case report and review of the literature. *Infection* 2015;43:777–81.
556. De Groote M, Frank DN, Dowell E, et al. *Lactobacillus rhamnosus* GG bacteremia associated with probiotic use in a child with short gut syndrome. *Pediatr Infect Dis J* 2005;24(3):278–80.
557. Sato S, Uchida T, Kuwana S, et al. Bacteremia induced by *Bifidobacterium breve* in a newborn with cloacal exstrophy. *Paediatr Int* 2016;58(11):1226–8.
558. Sanders ME, Merenstein DJ, Ouwehand AC, et al. Probiotic use in at-risk populations. *J Am Pharm Assoc* 2016;56(6):680–6.
559. Aaron JG, Sobieszczyk ME, Weiner SD, et al. *Lactobacillus rhamnosus* endocarditis after upper endoscopy. *Open Forum Infect Dis* 2017;4(2):ofx085.
560. Franko B, Vaillant M, Recule C, et al. *Lactobacillus paracasei* endocarditis in a consumer of probiotics. *Med Mal Infect* 2013;43(4):171–3.

561. Kato K, Funabashi N, Takaoka H, et al. Lactobacillus paracasei endocarditis in a consumer of probiotics with advanced and severe bicuspid aortic valve stenosis complicated with diffuse left ventricular mid-layer fibrosis. *Int J Cardiol* 2016;224:157–61.
562. Elias J, Bozzo P, Einarson A. Are probiotics safe for use during pregnancy and lactation?. *Can Fam Physician* 2011;57(3):299–301.
563. Royal Australian College of General Practitioners. Probiotics in pregnancy for infant atopic eczema. 2016. At: www.racgp.org.au/clinical-resources/clinical-guidelines/handi/conditions/children/probiotics-in-pregnancy-for-infant-atopic-eczema
564. Jarde A, Lewis-Mikhael A, Moayyedi P, et al. Pregnancy outcomes in women taking probiotics or prebiotics: a systematic review and meta-analysis. *BMC Pregnancy Childbirth* 2018;18:14.
565. Sheyholislami H, Connor KL. Are probiotics and prebiotics safe for use during pregnancy and lactation? A systematic review and meta-analysis. *Nutrients* 2021;13(7):2382.
566. Davidson SJ, Barrett HL, Price SA, et al. Probiotics for preventing gestational diabetes. *Cochrane Database of Systematic Reviews* 2021, Issue 4.
567. North American Menopause Society. Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of the North American Menopause Society. *Menopause* 2015;22(11):1155–72.
568. Myers SP, Vigar V. Effects of a standardised extract of Trifolium pratense (Promensil) at a dosage of 80mg in the treatment of menopausal hot flushes: a systematic review and meta-analysis. *Phytomedicine* 2017;24:141–7.
569. Kanady W, Barańska A, Błaszczyk A, et al. Evaluation of clinical meaningfulness of red clover (Trifolium pratense L) extract to relieve hot flushes and menopausal symptoms in peri- and post-menopausal women: a systematic review and meta-analysis of randomized controlled trials. *Nutrients* 2021;13(4):1258.
570. Lagari VS, Levis S. Phytoestrogens for menopausal bone loss and climacteric symptoms. *J Steroid Biochem Mol Biol* 2014;139:294–301.
571. Abdi F, Alimoradi Z, Haqi P, et al. Effects of phytoestrogens on bone mineral density during the menopause transition: a systematic review of randomized, controlled trials. *Climacteric* 2016;19(6):535–45.
572. Lambert MNT, Hu LM, Jeppesen PB. A systematic review and meta-analysis of the effects of isoflavone formulations against estrogen-deficient bone resorption in peri- and postmenopausal women. *Am J Clin Nutr* 2017;106(3):801–11.
573. Sansai K, Na Takuathung M, Khatsri R, et al. Effects of isoflavone interventions on bone mineral density in postmenopausal women: a systematic review and meta-analysis of randomized controlled trials. *Osteoporos Int* 2020;31(10):1853–64.
574. Schmidt M, Arjomand-Wolkart K, Birkhauser MH, et al. Consensus: soy isoflavones as a first-line approach to the treatment of menopausal vasomotor complaints. *Gynecol Endocrinol* 2016;32(6):427–30.
575. Chen L, Ko N, Chen K. Isoflavone supplements for menopausal women: a systematic review. *Nutrients* 2019;11(11):2649.
576. Orr A, Parker R. Red clover causing symptoms suggestive of methotrexate toxicity in a patient on high-dose methotrexate. *Menopause Int* 2013;19(3):133–4.
577. Hasan Y, Schoenherr D, Martinez AA, et al. Prostate-specific natural health products (dietary supplements) radiosensitize normal prostate cells. *Int J Radiat Oncol Biol Phys* 2010;76(3):896–904.
578. Galizia I, Oldani L, Macritchie K, et al. S-adenosyl methionine (SAME) for depression in adults. *Cochrane Database of Systematic Reviews* 2016, Issue 10.
579. Guo T, Chang L, Xiao Y, et al. S-adenosyl-L-methionine for the treatment of chronic liver disease: a systematic review and meta-analysis. *PLoS One* 2015;10(3):e0122124.
580. Noureddin M, Sander-Struckmeier S, Mato JM. Early treatment efficacy of S-adenosylmethionine in patients with intrahepatic cholestasis: a systematic review. *World J Hepatol* 2020;12(2):46–63.
581. Sharma A, Gerborg P, Bottiglieri T, et al. S-adenosylmethionine (SAME) for neuropsychiatric disorders: a clinician-oriented review of research. *J Clin Psychiatry* 2017;78(6):e656–67.
582. Rutjes AWS, Nüesch E, Reichenbach S, et al. S-adenosylmethionine for osteoarthritis of the knee or hip. *Cochrane Database of Systematic Reviews* 2009, Issue 4.
583. De-Silva V, El-Metwally A, Ernst E, et al. Evidence for the efficacy of complementary and alternative medicines in the management of osteoarthritis: a systematic review. *Rheumatology (Oxford)* 2011;50(5):911–20.
584. Drugs and Lactation Database (LactMed). SAM-e. 2021. At: www.ncbi.nlm.nih.gov/books/NBK501870
585. Mischoulon D, Price LH, Carpenter LL, et al. A double-blind, randomized, placebo-controlled clinical trial of S-adenosyl-L-methionine (SAME) versus escitalopram in major depressive disorder. *J Clin Psychiatry* 2014;75(4):370–6.
586. Martindale: The complete drug reference. Saw palmetto; [updated Jul 2023]. At: www.medicinescomplete.com/#/content/martindale/921-s?hsp=aw%20palmetto
587. European Medicines Agency. European Union herbal monograph on *Serenoa repens* (W. Bartram) Small, fructus. 2015. At: www.ema.europa.eu/en/medicines/herbal/sabalisserrulatae-fructus
588. Tacklind J, MacDonald R, Rutks I, et al. *Serenoa repens* for benign prostatic hyperplasia. *Cochrane Database of Systematic Reviews* 2012, Issue 12.
589. Vela-Navarrete R, Alcaraz A, Rodriguez-Antolin A, et al. Efficacy and safety of a hexanic extract of *Serenoa repens* (Permixon®) for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH): systematic review and meta-analysis of randomised controlled trials and observational studies. *BJU Int* 2018;122(6):1049–65.
590. Russo GI, Scandura C, Di Mauro M, et al. Clinical efficacy of *Serenoa repens* versus placebo versus alpha-blockers for the treatment of lower urinary tract symptoms/benign prostatic enlargement: a systematic review and network meta-analysis of randomized placebo-controlled clinical trials. *Eur Urol Focus* 2021;7(2):420–31.
591. Anceschi R, Blisi M, Ghidini N, et al. *Serenoa repens* (Permixon®) reduces intra- and postoperative complications of surgical treatments of benign prostatic hyperplasia. *Minerva Urol Nefrol* 2010;62(3):219–23.
592. Neff KD, Sandoval KP, de Castro LEF, et al. Factors associated with intraoperative floppy iris syndrome. *Ophthalmology* 2009;116(4):658–63.
593. Cheema P, El-Mefty O, Jazieh AR. Intraoperative haemorrhage associated with the use of extract of saw palmetto herb: a case report and review of literature. *J Intern Med* 2001;250(2):167–9.
594. North American Menopause Society. The 2023 nonhormone therapy position statement of The North American Menopause Society. *Menopause* 2023;30(6):573–90.
595. European Medicines Agency. Assessment report on Glycine max(L) Merr., semen. 2018. At: www.ema.europa.eu/en/medicines/herbal/glycini-semen
596. Rietjens IMCM, Louisse J, Beekmann K. The potential health effects of dietary phytoestrogens. *Br J Pharmacol* 2017;174(11):1263–80.
597. Cui C, Birru RL, Snitz BE, et al. Effects of soy isoflavones on cognitive function: a systematic review and meta-analysis of randomized controlled trials. *Nutr Rev* 2020;78(2):134–44.
598. Qin Y, Niu K, Zeng Y, et al. Isoflavones for hypercholesterolaemia in adults. *Cochrane Database of Systematic Reviews* 2013, Issue 6.
599. Tokede OA, Onabanjo TA, Yansane A, et al. Soy products and serum lipids: a meta-analysis of randomised controlled trials. *Br J Nutr* 2015;114(6):831–43.
600. Moradi M, Daneshzad E, Azadbakht L. The effects of isolated soy protein, isolated soy isoflavones and soy protein containing isoflavones on serum lipids in postmenopausal women: a systematic review and meta-analysis. *Crit Rev Food Sci Nutr* 2020;60(20):3141–28.
601. Vandenplas Y. Prevention and management of cow's milk allergy in non-exclusively breastfed infants. *Nutrients* 2017;9(7):E731.
602. Vandenplas Y, Castrellon PG, Rivas R, et al. Safety of soya-based infant formulas in children. *Br J Nutr* 2014;111(8):1340–60.
603. Lethaby A, Marjoribanks J, Kronenberg F, et al. Phytoestrogens for menopausal vasomotor symptoms. *Cochrane Database of Systematic Reviews* 2013, Issue 12.
604. Kerstetter JE, Wall DE, O'Brien KO, et al. Meat and soy protein affect calcium homeostasis in healthy women. *J Nutr* 2006;136(7):1890–5.
605. National Health and Medical Research Council. Infant feeding guidelines. Canberra: NHMRC; 2012.
606. Peng WX, Li HD, Zhou HH. Effect of daidzein on CYP1A2 activity and pharmacokinetics of theophylline in healthy volunteers. *Eur J Clin Pharmacol* 2003;59(3):237–41.

607. Serban MC, Sahebkar A, Dragan S, et al. A systematic review and meta-analysis of the impact of spirulina supplementation on plasma lipid concentrations. *Clin Nutr* 2016;35(4):842–51.
608. Huang H, Liao D, Pu R, et al. Quantifying the effects of spirulina supplementation on plasma lipid and glucose concentrations, body weight, and blood pressure. *Diabetes Metab Syndr Obes* 2018;11:729–42.
609. Hamedifard Z, Milajerdi A, Reiner Z, et al. The effects of spirulina on glycemic control and serum lipoproteins in patients with metabolic syndrome and related disorders: a systematic review and meta-analysis of randomized controlled trials. *Phytother Res* 2019;33(10):2609–21.
610. Moradi S, Ziaei R, Foshati S, et al. Effects of spirulina supplementation on obesity: a systematic review and meta-analysis of randomized clinical trials. *Complement Ther Med* 2019;47:102211.
611. Zarezadeh M, Faghfouri A, Radkhan N, et al. Spirulina supplementation and anthropometric indices: a systematic review and meta-analysis of controlled clinical trials. *Phytother Res* 2020;35(2):577–86.
612. Drugs and Lactation Database (LactMed). Spirulina. 2021. At: www.ncbi.nlm.nih.gov/books/NBK501849
613. Iwasa M, Yamamoto M, Tanaka Y, et al. Spirulina-associated hepatotoxicity. *Am J Gastroenterol* 2002;97(12):3212–3.
614. Savranoglu S, Tumer TB. Inhibitory effects of Spirulina platensis on carcinogen-activating cytochrome P450 isozymes and potential for drug interactions. *Int J Toxicol* 2013;32(5):376–84.
615. Suliburska J, Szulinska M, Tinkov AA, et al. Effect of Spirulina maxima supplementation on calcium, magnesium, iron, and zinc status in obese patients with treated hypertension. *Biol Trace Elem Res* 2016;173:1–6.
616. Gutiérrez-Salmeán G, Fabila-Castillo L, Chamorro-Cevallos G, et al. Nutritional and toxicological aspects of spirulina (arthrosipira). *Nutr Hosp* 2015;32(1):34–40.
617. Martindale: The complete drug reference. Phenylalanine; [updated Nov 2022]. At: www.medicinescomplete.com/#/content/martindale/610-k?hsp=phenylalanine
618. Therapeutic Goods Administration. Arthrosipira platensis. 2011. At: www.tga.gov.au/compositional-guideline/arthrosipira-platensis
619. Linde K, Berner MM, Kriston L. St John's wort for major depression. *Cochrane Database of Systematic Reviews* 2008, Issue 4.
620. Apaydin EA, Maher AR, Shanman R, et al. A systematic review of St. John's wort for major depressive disorder. *Syst Rev* 2016;5:148.
621. Ng QX, Venkatanarayanan N, Ho CYX. Clinical use of Hypericum perforatum (St John's wort) in depression: a meta-analysis. *J Affect Disord* 2017;210:211–21.
622. Zhao X, Zhang H, Wu Y, et al. The efficacy and safety of St. John's wort extract in depression therapy compared to SSRIs in adults: a meta-analysis of randomized clinical trials. *Adv Clin Exp Med* 2023;32(2):151–61.
623. Liu YR, Jiang YL, Huang RQ, et al. Hypericum perforatum L. preparations for menopause: a meta-analysis of efficacy and safety. *Climacteric* 2014;17(4):325–35.
624. European Medicines Agency. European Union herbal monograph on Hypericum perforatum L., herba. 2022. At: www.ema.europa.eu/en/medicines/herbal/hyperici-herba-0
625. Hoban CL, Byard RW, Musgrave IF. A comparison of patterns of spontaneous adverse drug reaction reporting with St John's wort and fluoxetine during the period 2000–2013. *Clin Exp Pharmacol Physiol* 2015;42(7):747–51.
626. Ferrara M, Mungai F, Starace F. St John's wort (Hypericum perforatum)-induced psychosis: a case report. *J Med Case Rep* 2017;11:137.
627. Bove GM. Acute neuropathy after exposure to sun in a patient treated with St John's wort. *Lancet* 1998;352(9134):1121–2.
628. Drugs and Lactation Database (LactMed). St John's wort. 2021. At: www.ncbi.nlm.nih.gov/books/NBK501770
629. Imai H, Kotegawa T, Tsutsumi K, et al. The recovery time-course of CYP3A after induction by St John's wort administration. *Br J Clin Pharmacol* 2008;65(5):701–7.
630. Bauer S, Stormer E, John A, et al. Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St John's wort in renal transplant patients. *Br J Clin Pharmacol* 2003;55(2):203–11.
631. Medicines and Healthcare products Regulatory Agency. Herbal ingredient St John's wort may interact with all antiepileptics. *MHRA Drug Safety Update* 2007;1(4):7.
632. Therapeutic Goods Administration. St John's wort: information sheet for health care professionals. 2000. At: www.tga.gov.au/alert/st-johns-wort-information-sheet-health-care-professionals
633. Dolton MJ, Mikus G, Weiss J, et al. Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing. *J Antimicrob Chemother* 2014;69(6):1633–41.
634. Rossi S, ed. Drug interactions. Australian medicines handbook; [updated Jan 2023]. At: <https://amhonline.amh.net.au/interactions>
635. Faculty of Sexual and Reproductive Healthcare. Clinical guidance: drug interactions with hormonal contraception. London: FSRH; 2022.
636. Jiang X, Blair EYL, McLachlan AJ. Investigation of the effects of herbal medicines on warfarin response in healthy subjects: a population pharmacokinetic-pharmacodynamic modeling approach. *J Clin Pharmacol* 2006;46(11):1370–8.
637. Hojo Y, Echizenya M, Ohkubo T, et al. Drug interaction between St John's wort and zolpidem in healthy subjects. *J Clin Pharm Ther* 2011;36(6):711–5.
638. Nahrstedt A, Butterweck V. Lessons learned from herbal medicinal products: the example of St John's wort (perpendicular). *J Nat Prod* 2010;73(5):1015–21.
639. Cao H, Yang G, Wang Y, et al. Complementary therapies for acne vulgaris. *Cochrane Database of Systematic Reviews* 2015, Issue 1.
640. Saviia K, Le JT, Pucker AD. Tea tree oil for Demodex blepharitis. *Cochrane Database of Systematic Reviews* 2020, Issue 6.
641. Kairey L, Agnew T, Bowles EJ, et al. Efficacy and safety of Melaleuca alternifolia (tea tree) oil for human health – a systematic review of randomized controlled trials. *Front Pharmacol* 2023;14.
642. Barker SC, Altman PM. A randomised, assessor blind, parallel group comparative efficacy trial of three products for the treatment of head lice in children – melaleuca oil and lavender oil, pyrethrins and piperonyl butoxide, and a 'suffocation' product. *BMC Dermatol* 2010;10:6.
643. Barker SC, Altman PM. An ex vivo, assessor blind, randomised, parallel group, comparative efficacy trial of the ovicidal activity of three pediculicides after a single application – melaleuca oil and lavender oil, eucalyptus oil and lemon tea tree oil, and a 'suffocation' pediculicide. *BMC Dermatol* 2011;11:14.
644. Buck DS, Nidor DM, Addino JG. Comparison of two topical preparations for the treatment of onychomycosis: Melaleuca alternifolia (tea tree) oil and clotrimazole. *J Fam Pract* 1994;38(6):601–5.
645. Martin KW, Ernst E. Herbal medicines for treatment of fungal infections: a systematic review of controlled clinical trials. *Mycoses* 2004;47(3–4):87–92.
646. Crawford F, Hollis S. Topical treatments for fungal infections of the skin and nails of the foot. *Cochrane Database of Systematic Reviews* 2007, Issue 3.
647. Drugs and Lactation Database (LactMed). Tea tree oil. 2023. At: www.ncbi.nlm.nih.gov/books/NBK501884
648. Rogerson S, Riches CJ, Jennings C, et al. The effect of five weeks of Tribulus terrestris supplementation on muscle strength and body composition during pre-season training in elite rugby league players. *J Strength Cond Res* 2007;21(2):348–53.
649. Sha'ari N, Woon LS, Sidi H, et al. Beneficial effects of natural products on female sexual dysfunction: a systematic review and meta-analysis. *Phytomedicine* 2021;93.
650. Sanagoo S, Sadeghzadeh Oskouei B, Gassab Abdollahi N, et al. Effect of Tribulus terrestris L. on sperm parameters in men with idiopathic infertility: a systematic review. *Complement Ther Med* 2019;42:95–103.
651. Qureshi A, Naughton DP, Petroczi A. A systematic review on the herbal extract Tribulus terrestris and the roots of its putative aphrodisiac and performance enhancing effect. *J Diet Suppl* 2014;11(1):64–79.
652. Gama CRB, Lasmar R, Gama GF, et al. Clinical assessment of Tribulus terrestris extract in the treatment of female sexual dysfunction. *Clin Med Insights Womens Health* 2014;7:45–50.
653. Talasaz AH, Abbasi MR, Abkhiz S, et al. Tribulus terrestris-induced severe nephrotoxicity in a young healthy male. *Nephrol Dial Transplant* 2010;25(11):3792–3.
654. Ryan M, Lazar I, Nadasdy GM, et al. Acute kidney injury and hyperbilirubinemia in a young male after ingestion of Tribulus terrestris. *Clin Nephrol* 2015;83(3):177–83.
655. Ivanova A, Serly J, Dinchev D, et al. Screening of some saponins and phenolic components of Tribulus terrestris and Smilax excelsa as MDR modulators. *In Vivo* 2009;23(4):545–50.

656. Martindale: The complete drug reference. Tribulus terrestris; [updated Aug 2023]. At: www.medicinescomplete.com/#/content/martindale/8927-w?hspl=tribulus
657. Martindale: The complete drug reference. Turmeric; [updated Aug 2023]. At: www.medicinescomplete.com/#/content/martindale/2415-q?hspl=turmeric
658. Sahebkar A, Henrotin Y. Analgesic efficacy and safety of curcuminoids in clinical practice: a systematic review and meta-analysis of randomized controlled trials. *Pain Med* 2016;17(6):1192–202.
659. Onakpoya IJ, Spencer EA, Perera R, et al. Effectiveness of curcuminoids in the treatment of knee osteoarthritis: a systematic review and meta-analysis of randomized clinical trials. *Int J Rheum Dis* 2017;20(4):420–33.
660. Wang Z, Singh A, Jones G, et al. Efficacy and safety of turmeric extracts for the treatment of knee osteoarthritis: a systematic review and meta-analysis of randomised controlled trials. *Curr Rheumatol Rep* 2021;23:11.
661. Zeng L, Yang T, Yang K, et al. Efficacy and safety of curcumin and Curcuma longa extract in the treatment of arthritis: a systematic review and meta-analysis of randomized controlled trial. *Front Immunol* 2022;13.
662. Tabrizi R, Vakili S, Akbari M, et al. The effects of curcumin-containing supplements on biomarkers of inflammation and oxidative stress: a systematic review and meta-analysis of randomized controlled trials. *Phytother Res* 2019;33(2):253–62.
663. White CM, Pasupuleti V, Roman YM, et al. Oral turmeric/curcumin effects on inflammatory markers in chronic inflammatory diseases: a systematic review and meta-analysis of randomized controlled trials. *Pharmacol Res* 2019;146:104280.
664. Fernandez-Lazaro D, Mielgo-Ayuso J, Seco-Calvo J, et al. Modulation of exercise-induced muscle damage, inflammation, and oxidative markers by curcumin supplementation in a physically active population: a systematic review. *Nutrients* 2020;12(2):501.
665. Gaffey A, Slater H, Porritt K, et al. The effects of curcuminoids on musculoskeletal pain: a systematic review. *JBI Database System Rev Implement Rep* 2017;15(2):486–516.
666. Pakfetrat M, Basiri F, Malekmakan L, et al. Effects of turmeric on uremic pruritus in end stage renal disease patients: a double-blind randomized clinical trial. *J Nephrol* 2014;27(2):203–7.
667. European Medicines Agency. European Union herbal monograph on Curcuma longa L., rhizoma. 2018. At: www.ema.europa.eu/en/medicines/herbal/curcumae-longae-rhizoma
668. Therapeutic Goods Administration. Medicines containing turmeric or curcumin – risk of liver injury. 2023. At: www.tga.gov.au/news/safety-alerts/medicines-containing-turmeric-or-curcumin-risk-liver-injury
669. Lombardi N, Crescioli G, Maggini V, et al. Acute liver injury following turmeric use in Tuscany: an analysis of the Italian Phytovigilance database and systematic review of case reports. *Br J Clin Pharmacol* 2021;87(3):741–53.
670. Medsafe. Beware turmeric/curcumin containing products can interact with warfarin. 2018. At: <https://www.medsafe.govt.nz/safety/EWS/2018/Turmeric.asp>
671. Somasundaram S, Edmund NA, Moore DT, et al. Dietary curcumin inhibits chemotherapy-induced apoptosis in models of human breast cancer. *Cancer Res* 2002;62(13):3868–75.
672. Volak LP, Ghirmal S, Cashman JR, et al. Curcuminoids inhibit multiple human cytochromes P450, UDP-glucuronosyltransferase, and sulfotransferase enzymes, whereas piperine is a relatively selective CYP3A4 inhibitor. *Drug Metab Dispos* 2008;36(8):1594–605.
673. Rasyid A, Rahman ARA, Jaalam K, et al. Effect of different curcumin dosages on human gall bladder. *Asia Pac J Clin Nutr* 2002;11(4):314–8.
674. Shafabakhsh R, Asemi Z, Reiner Z, et al. The effects of nano-curcumin on metabolic status in patients with diabetes on hemodialysis, a randomized, double blind, placebo-controlled trial. *Iran J Kidney Dis*. 2020;14(4):290–9.
675. Tang M, Larson-Meyer DE, Liebman M. Effect of cinnamon and turmeric on urinary oxalate excretion, plasma lipids, and plasma glucose in healthy subjects. *Am J Clin Nutr* 2008;87(5):1262–7.
676. Lopes-Rodrigues V, Sousa E, Vasconcelos MH. Curcumin as a modulator of P-glycoprotein in cancer: challenges and perspectives. *Pharmaceuticals (Basel)* 2016;9(4):71.
677. Kusahara H, Furuie H, Inano A, et al. Pharmacokinetic interaction study of sulphasalazine in healthy subjects and the impact of curcumin as an in vivo inhibitor of BCRP. *Br J Pharmacol* 2012;166(6):1793–803.
678. Drugs and Lactation Database (LactMed). Turmeric. 2022. At: www.ncbi.nlm.nih.gov/books/NBK501846
679. Eke-Okoru UJ, Raffa RB, Pergolizzi JV, et al. Curcumin in turmeric: basic and clinical evidence for a potential role in analgesia. *J Clin Pharm Ther* 2018;43(4):460–6.
680. Shoba G, Joy D, Joseph T, et al. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. *Planta Med* 1998;64(4):353–6.
681. Leach MJ, Page AT. Herbal medicine for insomnia: a systematic review and meta-analysis. *Sleep Med Rev* 2015;24:1–12.
682. Zhang X, Lu Y, Lv F, et al. Valerian for insomnia on subjective and objective sleep parameters: a meta-analysis of randomized controlled trials. *Curr Sleep Medicine Rep* 2023;9(3):1–14.
683. Miyasaka LS, Atallah AN, Soares B. Valerian for anxiety disorders. *Cochrane Database of Systematic Reviews* 2006, Issue 4.
684. European Medicines Agency. European Union herbal monograph on Valeriana officinalis L., radix. 2016. At: <https://www.ema.europa.eu/en/medicines/herbal/valeriana-radix>
685. Toovey OTR, Edmond IR, Makris N. Acute severe hyponatraemia secondary to polydipsia and associated herbal remedy use. *BMJ Case Rep* 2016;bcr2016216348.
686. Therapeutic Goods Administration. Valerian (Valeriana officinalis). 2020. At: www.tga.gov.au/alert/valerian-valeriana-officinalis
687. Martindale: The complete drug reference. Valerian; [updated Aug 2023]. At: www.medicinescomplete.com/#/content/martindale/14009-h?hspl=valerian
688. Garges HP, Varia I, Doraiswamy PM. Cardiac complications and delirium associated with valerian root withdrawal. *JAMA* 1998;280(18):1566–7.
689. Norwegian Porphyria Centre. The drug database for acute porphyria. 2023. At: www.drugs-porphyrria.org
690. Martindale: The complete drug reference. Valerian; [updated Aug 2023]. At: www.medicinescomplete.com/#/content/martindale/14009-h?hspl=valerian
691. Mohamed MF, Frye RF. Effects of herbal supplements on drug glucuronidation: Review of clinical, animal, and in vitro studies. *Planta Med* 2011;77(4):311–21.
692. Drugs and Lactation Database (LactMed). Valerian. 2021. At: www.ncbi.nlm.nih.gov/books/NBK501815
693. European Medicines Agency. European Union herbal monograph on Salix [various species including S. purpurea L., S. daphnoides Willd., S. fragilis L.], cortex. 2017. At: www.ema.europa.eu/en/medicines/herbal/salicyc-cortex
694. Oltean H, Robbins C, vanTulder MW, et al. Herbal medicine for low-back pain. *Cochrane Database of Systematic Reviews* 2014, Issue 12.
695. Martindale: The complete drug reference. Salix; [updated May 2023]. At: www.medicinescomplete.com/#/content/martindale/11536-n?hspl=willow%20bark
696. Krivoy N, Pavlotzky E, Chrubasik S, et al. Effect of salicyc cortex extract on human platelet aggregation. *Planta Med* 2001;67(3):209–12.
697. Martindale: The complete drug reference. Aspirin; [updated Aug 2023]. At: www.medicinescomplete.com/#/content/martindale/2601-s?hspl=aspirin%20entent%2Fmartindale%2F2601-s%232601-a2-f
698. Drugs and Lactation Database (LactMed). Willow bark. 2021. At: www.ncbi.nlm.nih.gov/books/NBK501904
699. Therapeutic Goods Administration. Required Advisory Statements for Medicine Labels (RASML) No. 6. 2022. At: www.tga.gov.au/resources/resource/guidance/required-advisory-statements-medicine-labels-rasml